116917	\N	Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.	{"Hasunuma Tomoko","Tohkin Masahiro","Kaniwa Nahoko","Jang In-Jin","Yimin Cui","Kaneko Masaru","Saito Yoshiro","Takeuchi Masahiro","Watanabe Hiroshi","Yamazoe Yasushi","Uyama Yoshiaki","Kawai Shinichi"}	British journal of clinical pharmacology	6	\N	\N	2016	26774055	\N	\N	\N	2	f	\N
116921	\N	Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.	{"Wang Can","Wang Ping","Yang Li-Ping","Pan Jing","Yang Xue","Ma Hong-Ying"}	Epilepsy research	5	\N	\N	2017	28315807	\N	\N	\N	2	f	\N
116925	\N	Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.	{"Takahashi H","Kashima T","Nomizo Y","Muramoto N","Shimizu T","Nasu K","Kubota T","Kimura S","Echizen H"}	Clinical pharmacology and therapeutics	5	\N	\N	1998	9630825	\N	\N	\N	2	f	\N
116927	\N	Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.	{"Odani A","Hashimoto Y","Otsuki Y","Uwai Y","Hattori H","Furusho K","Inui K"}	Clinical pharmacology and therapeutics	9	\N	\N	1997	9333104	\N	\N	\N	2	f	\N
116946	\N	Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.	{"Kim Kyoung-Ah","Song Wan-Geun","Lee Hae-Mi","Joo Hyun-Jin","Park Ji-Young"}	Molecular biology reports	11	\N	\N	2014	25069408	\N	\N	\N	2	f	\N
116950	\N	Allele and genotype frequencies of CYP2C9 in a Korean population.	{"Bae Jung-Woo","Kim Hyun-Kyung","Kim Ji-Hong","Yang Sang-In","Kim Mi-Jeong","Jang Choon-Gon","Park Young-Seo","Lee Seok-Yong"}	British journal of clinical pharmacology	10	\N	\N	2005	16187974	\N	\N	\N	2	f	\N
116952	\N	A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China.	{"Xiong Yuyu","Wang Ming","Fang Ke","Xing Qinghe","Feng Guoyin","Shen Lu","He Lin","Qin Shengying"}	Genomics	5	\N	\N	2011	21126569	\N	\N	\N	2	f	\N
116957	\N	CYP2C9 allele variants in Chinese hypertension patients and healthy controls.	{"Yu Bang-ning","Luo Chen-Hui","Wang Dan","Wang An","Li Zhi","Zhang Wei","Mo Wei","Zhou Hong-Hao"}	Clinica chimica acta; international journal of clinical chemistry	10	\N	\N	2004	15369736	\N	\N	\N	2	f	\N
116962	\N	Genetic polymorphisms analysis of drug-metabolizing enzyme CYP2C9 in the Uyghur population.	{"Jin Tianbo","Xun Xiaojie","Du Shuli","Geng Tingting","Wang Hong","Feng Tian","Chen Chen","Yuan Dongya","Kang Longli"}	Xenobiotica; the fate of foreign compounds in biological systems	8	\N	\N	2016	26610168	\N	\N	\N	2	f	\N
116964	\N	Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population.	{"Ding Yipeng","Yang Danlei","Zhou Long","He Ping","Yao Jinjian","Xie Pingdong","Lin Daobo","Sun Dingwei","Sun Pei","Li Quanni","Geng Tingting","Jin Tianbo"}	International journal of clinical and experimental medicine	0	\N	\N	2015	26885033	\N	\N	\N	2	f	\N
116968	\N	Gender specific association of CYP2C9*3 with hyperlipidaemia in Chinese.	{"Luo Chen-Hui","Wang An","Zhu Rong-Hua","Zhang Wei-Xia","Mo Wei","Yu Bang-Ning","Chen Guo-Lin","Ou-Yang Dong-Sheng","Duan Xiao-Hong","Abd El-Aty A M","Zhou Hong-Hao"}	British journal of clinical pharmacology	12	\N	\N	2005	16305587	\N	\N	\N	2	f	\N
116981	\N	Systematic characterization and comparison of the CYP2C9 variability of the Orang Asli in Malaysia with 12 populations.	{"Teh Lay Kek","Subramaniam Vinothini","Tuan Abdu Aziz Tuan Azlin","Lee Lian Shien","Ismail Mohamed Izwan","Yu Choo Yee","Ang Geik Yong","James Johari Richard","Ismet Rose Iszati","Sahak Noor Saadah","Ahmad Aminuddin","Rahman Thuhairah Abdul","Nor Ghazali Fadzilah Mohd","Shaari SyahrulAzlin","Omar Mustaffa","Ismail Adzrool Idzwan","Md Isa Kamarudzaman","Salleh Hood","Salleh Mohd Zaki"}	Drug metabolism and pharmacokinetics	8	\N	\N	2016	27325019	\N	\N	\N	2	f	\N
116984	\N	Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China.	{"Yang Z F","Cui H W","Hasi T","Jia S Q","Gong M L","Su X L"}	Genetics and molecular research : GMR	9	\N	\N	2010	20845310	\N	\N	\N	2	f	\N
114365	\N	Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California.	{"Wan Y J","Poland R E","Han G","Konishi T","Zheng Y P","Berman N","Lin K M"}	Pharmacogenetics	8	\N	\N	2001	11505219	\N	\N	\N	2	f	\N
116986	\N	Polymorphic analysis of CYP2C9 gene in Vietnamese population.	{"Vu Nhung Phuong","Ma Thuong Thi Huyen","Tran Ngoc Thi Bich","Huynh Hue Thi Thu","Nguyen Ton Dang","Nguyen Duong Thuy","Van Nong Hai","Lee Ming Ta Michael","Nguyen Ha Hai"}	Molecular biology reports	10	\N	\N	2018	29978384	\N	\N	\N	2	f	\N
117005	\N	Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.	{"Scordo M G","Aklillu E","Yasar U","Dahl M L","Spina E","Ingelman-Sundberg M"}	British journal of clinical pharmacology	10	\N	\N	2001	11678789	\N	\N	\N	2	f	\N
116635	\N	The largest prospective warfarin-treated cohort supports genetic forecasting.	{"Wadelius Mia","Chen Leslie Y","Lindh Jonatan D","Eriksson Niclas","Ghori Mohammed J R","Bumpstead Suzannah","Holm Lennart","McGinnis Ralph","Rane Anders","Deloukas Panos"}	Blood	1	\N	\N	2009	18574025	\N	\N	\N	2	f	\N
113892	\N	Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients.	{"Pautas E","Moreau C","Gouin-Thibault I","Golmard J-L","Mahé I","Legendre C","Taillandier-Hériche E","Durand-Gasselin B","Houllier A-M","Verrier P","Beaune P","Loriot M-A","Siguret V"}	Clinical pharmacology and therapeutics	1	\N	\N	2010	19794411	\N	\N	\N	2	f	\N
113897	\N	Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.	{"Mazzaccara Cristina","Conti Valeria","Liguori Rosario","Simeon Vittorio","Toriello Mario","Severini Angelo","Perricone Corrado","Meccariello Alfonso","Meccariello Pasquale","Vitale Dino Franco","Filippelli Amelia","Sacchetti Lucia"}	PloS one	0	\N	\N	2013	23990957	\N	\N	\N	2	f	\N
117011	\N	The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.	{"van der Weide J","Steijns L S","van Weelden M J","de Haan K"}	Pharmacogenetics	6	\N	\N	2001	11434505	\N	\N	\N	2	f	\N
117018	\N	Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.	{"LLerena Adrián","Dorado Pedro","Berecz Roland","González Antonio P","Peñas-LLedó Eva M"}	European journal of clinical pharmacology	2	\N	\N	2004	14726986	\N	\N	\N	2	f	\N
117020	\N	The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.	{"Sandberg Mia","Johansson Inger","Christensen Magnus","Rane Anders","Eliasson Erik"}	Drug metabolism and disposition: the biological fate of chemicals	5	\N	\N	2004	15100169	\N	\N	\N	2	f	\N
117024	\N	Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.	{"García-Martín Elena","Martínez Carmen","Tabarés Beatriz","Frías Jesús","Agúndez José A G"}	Clinical pharmacology and therapeutics	8	\N	\N	2004	15289789	\N	\N	\N	2	f	\N
117028	\N	Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.	{"Scordo Maria G","Spina Edoardo","Dahl Marja-Liisa","Gatti Giuliana","Perucca Emilio"}	Basic & clinical pharmacology & toxicology	11	\N	\N	2005	16236141	\N	\N	\N	2	f	\N
117108	\N	Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population.	{"Hadjipanagi Despina","Chrysanthou Stephanie","Voskarides Konstantinos","Deltas Constantinos"}	BMC research notes	3	\N	\N	2014	24593903	\N	\N	\N	2	f	\N
117032	\N	Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding.	{"Blanco Gerardo","Martínez Carmen","Ladero Jose M","Garcia-Martin Elena","Taxonera Carlos","Gamito Francisco G","Diaz-Rubio Manuel","Agundez Jose A G"}	Pharmacogenetics and genomics	1	\N	\N	2008	18216720	\N	\N	\N	2	f	\N
117035	\N	Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.	{"López-Rodríguez Rosario","Novalbos Jesús","Gallego-Sandín Sonia","Román-Martínez Manuel","Torrado Juan","Gisbert Javier P","Abad-Santos Francisco"}	Pharmacological research	7	\N	\N	2008	18694831	\N	\N	\N	2	f	\N
117037	\N	VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.	{"Markatos Christos N","Grouzi Elissavet","Politou Marianna","Gialeraki Argyri","Merkouri Efrosyni","Panagou Ioannis","Spiliotopoulou Ioanna","Travlou Anthi"}	Pharmacogenomics	11	\N	\N	2008	19018719	\N	\N	\N	2	f	\N
117042	\N	Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.	{"Ragia Georgia","Petridis Ioannis","Tavridou Anna","Christakidis Dimitrios","Manolopoulos Vangelis G"}	Pharmacogenomics	11	\N	\N	2009	19891554	\N	\N	\N	2	f	\N
117044	\N	VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.	{"Puehringer Helene","Loreth Ralph M","Klose Gudrun","Schreyer Brigitte","Krugluger Walter","Schneider Barbara","Oberkanins Christian"}	European journal of clinical pharmacology	6	\N	\N	2010	20376629	\N	\N	\N	2	f	\N
117049	\N	Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.	{"Botton Mariana Rodrigues","Bandinelli Eliane","Rohde Luis Eduardo Paim","Amon Luis Carlos","Hutz Mara Helena"}	British journal of clinical pharmacology	9	\N	\N	2011	21320153	\N	\N	\N	2	f	\N
117051	\N	Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population.	{"Buzková Helena","Pechandová Kristina","Danzig Vilém","Vareka Tomá","Perlik Frantisek","Zak Ales","Slanar Ondrej"}	Medical science monitor : international medical journal of experimental and clinical research	8	\N	\N	2012	22847201	\N	\N	\N	2	f	\N
117056	\N	Visual diagnosis: abnormal nails in an infant.	{"Cunningham Natalie P","Green Peter J"}	Pediatrics in review	11	\N	\N	2012	23118323	\N	\N	\N	2	f	\N
117058	\N	Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain.	{"Llerena A","Alvarez M","Dorado P","González I","Peñas-LLedó E","Pérez B","Cobaleda J","Calzadilla L R"}	The pharmacogenomics journal	6	\N	\N	2014	23959274	\N	\N	\N	2	f	\N
117064	\N	Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery.	{"Abohelaika S","Wynne H","Avery P","Kamali F"}	Journal of thrombosis and haemostasis : JTH	8	\N	\N	2015	26010205	\N	\N	\N	2	f	\N
117067	\N	The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia.	{"Mikstacki Adam","Zakerska-Banaszak Oliwia","Skrzypczak-Zielinska Marzena","Tamowicz Barbara","Prendecki Michał","Dorszewska Jolanta","Molinska-Glura Marta","Waszak Malgorzata","Slomski Ryszard"}	Journal of applied genetics	5	\N	\N	2017	27826892	\N	\N	\N	2	f	\N
117069	\N	Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects.	{"Guevara Natalia","Maldonado Cecilia","Uría Manuel","González Raquel","Ibarra Manuel","Alvariza Silvana","Carozzi Antonella","Azambuja Carlos","Fagiolino Pietro","Vázquez Marta"}	Pharmaceuticals (Basel, Switzerland)	8	\N	\N	2017	28820457	\N	\N	\N	2	f	\N
117074	\N	The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.	{"Martínez Carmen","García-Martín Elena","Blanco Gerardo","Gamito Francisco J G","Ladero José M","Agúndez José A G"}	British journal of clinical pharmacology	1	\N	\N	2005	15606441	\N	\N	\N	2	f	\N
117081	\N	Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients.	{"Spreafico M","Peyvandi F","Pizzotti D","Moia M","Mannucci P M"}	Journal of thrombosis and haemostasis : JTH	10	\N	\N	2003	14521618	\N	\N	\N	2	f	\N
117085	\N	The frequency of cytochrome P450 2C9 genetic variants in the Russian population and their associations with individual sensitivity to warfarin therapy.	{"Pchelina Sofya N","Sirotkina Olga V","Taraskina Anastasiya E","Vavilova Tatyana V","Shwarzman Alexander L","Schwartz Eugene I"}	Thrombosis research	0	\N	\N	2005	15617742	\N	\N	\N	2	f	\N
117087	\N	Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.	{"Wypasek Ewa","Branicka Agnieszka","Awsiuk Magdalena","Sadowski Jerzy","Undas Anetta"}	Thrombosis research	9	\N	\N	2014	25042728	\N	\N	\N	2	f	\N
117094	\N	Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan.	{"Mirzaev Karin B","Sychev Dmitry A","Ryzhikova Kristina A","Konova Olga D","Mammaev Suleiman N","Gafurov Daniyal M","Shuev Grigorij N","Grishina Elena A","Sozaeva Zhannet A"}	Genetic testing and molecular biomarkers	12	\N	\N	2017	29023140	\N	\N	\N	2	f	\N
117099	\N	Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population.	{"Krasniqi Valon","Dimovski Aleksandar","Bytyqi Hasime Qorraj","Eftimov Aleksandar","Šimičević Livija","Božina Nada"}	Arhiv za higijenu rada i toksikologiju	9	\N	\N	2017	28976882	\N	\N	\N	2	f	\N
114639	\N	Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations.	{"Sychev Dmitrij Alekseevitch","Shuev Grigorij Nikolaevich","Suleymanov Salavat Shejhovich","Ryzhikova Kristina Anatol'evna","Mirzaev Karin Badavievich","Grishina Elena Anatol'evna","Snalina Natalia Evgenievna","Sozaeva Zhannet Alimovna","Grabuzdov Anton Mikhailovich","Matsneva Irina Andreevna"}	Pharmacogenomics and personalized medicine	0	\N	\N	2017	28435307	\N	\N	\N	2	f	\N
117105	\N	Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe.	{"Buzoianu Anca D","Trifa Adrian P","Mureşanu Dafin F","Crişan Sorin"}	Journal of cellular and molecular medicine	12	\N	\N	2012	22863573	\N	\N	\N	2	f	\N
117118	\N	CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men.	{"Donner Kati M","Hiltunen Timo P","Suonsyrjä Timo","Hannila-Handelberg Tuula","Tikkanen Ilkka","Antikainen Miia","Hirvonen Ari","Kontula Kimmo"}	Journal of hypertension	10	\N	\N	2009	19593208	\N	\N	\N	2	f	\N
114132	\N	Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.	{"Arvanitidis Kostas","Ragia Georgia","Iordanidou Maria","Kyriaki Sofia","Xanthi Athanasia","Tavridou Anna","Manolopoulos Vangelis G"}	Fundamental & clinical pharmacology	8	\N	\N	2007	17635181	\N	\N	\N	2	f	\N
113905	\N	A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.	{"Duconge Jorge","Ramos Alga S","Claudio-Campos Karla","Rivera-Miranda Giselle","Bermúdez-Bosch Luis","Renta Jessicca Y","Cadilla Carmen L","Cruz Iadelisse","Feliu Juan F","Vergara Cunegundo","Ruaño Gualberto"}	PloS one	0	\N	\N	2016	26745506	\N	\N	\N	2	f	\N
117137	\N	Pharmacogenomics of warfarin dose requirements in Hispanics.	{"Cavallari Larisa H","Momary Kathryn M","Patel Shitalben R","Shapiro Nancy L","Nutescu Edith","Viana Marlos A G"}	Blood cells, molecules & diseases	2	\N	\N	2011	21185752	\N	\N	\N	2	f	\N
117139	\N	CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation.	{"Twardowschy Carlos Alexandre","Werneck Lineu César","Scola Rosana Herminia","De Paola Luciano","Silvado Carlos Eduardo"}	Arquivos de neuro-psiquiatria	4	\N	\N	2011	21537551	\N	\N	\N	2	f	\N
117141	\N	CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.	{"Santos Paulo Caleb Junior Lima","Dinardo Carla Luana","Schettert Isolmar Tadeu","Soares Renata Alonso Gadi","Kawabata-Yoshihara Liz","Bensenor Isabela Martins","Krieger José Eduardo","Lotufo Paulo Andrade","Pereira Alexandre Costa"}	European journal of clinical pharmacology	4	\N	\N	2013	22990331	\N	\N	\N	2	f	\N
114506	\N	Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations.	{"Roco Angela","Quiñones Luis","Agúndez José A G","García-Martín Elena","Squicciarini Valentina","Miranda Carla","Garay Joselyn","Farfán Nancy","Saavedra Iván","Cáceres Dante","Ibarra Carol","Varela Nelson"}	Frontiers in genetics	0	\N	\N	2012	23130019	\N	\N	\N	2	f	\N
117149	\N	Prevalence of CYP2C9 variants in the Mexican population.	{"Aguilar Bernardo","Rojas Julio C","Collados Maria T"}	Archives of medical research	5	\N	\N	2008	18375260	\N	\N	\N	2	f	\N
117152	\N	Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants.	{"Scibona P","Redal M A","Garfi L G","Arbelbide J","Argibay P F","Belloso W H"}	Genetics and molecular research : GMR	1	\N	\N	2012	22290467	\N	\N	\N	2	f	\N
114542	\N	Genetic polymorphism of CYP2D6 in Chinese subjects in Malaysia.	{"Ismail R","Teh L K","Amir J","Alwi Z","Lopez C G"}	Journal of clinical pharmacy and therapeutics	8	\N	\N	2003	12911679	\N	\N	\N	2	f	\N
117155	\N	CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study.	{"Saldaña-Cruz Ana Miriam","León-Moreno Lilia Carolina","Sánchez-Corona José","Santiago Daniel Alejandro Márquez-de","Mendoza-Carrera Francisco","Castro-Martínez Xochitl Helga","García-Zapién Alejandra Guadalupe","Morán-Moguel María Cristina","Flores-Martínez Silvia Esperanza"}	Genetic testing and molecular biomarkers	11	\N	\N	2016	27617498	\N	\N	\N	2	f	\N
117162	\N	Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.	{"Shahin Mohamed Hossam A","Khalifa Sherief I","Gong Yan","Hammad Lamiaa N","Sallam Mohamed T H","El Shafey Mostafa","Ali Shawky S","Mohamed Mohamed-Eslam F","Langaee Taimour","Johnson Julie A"}	Pharmacogenetics and genomics	3	\N	\N	2011	21228733	\N	\N	\N	2	f	\N
117164	\N	Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.	{"Smires F Z","Habbal R","Moreau C","Assaidi A","Loriot M A","Nadifi S"}	Pathologie-biologie	6	\N	\N	2013	23201087	\N	\N	\N	2	f	\N
117168	\N	Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.	{"Abdelhedi Rania","Bouayed Nouha Abdelmoula","Alfadhli Suad","Abid Leila","Rebai Ahmed","Kharrat Najla"}	Journal of genetics	12	\N	\N	2015	26690534	\N	\N	\N	2	f	\N
117170	\N	Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.	{"Afilal Driss","Basselam Mohamed Amine","Brakez Zahra","Chouham Said","Brehm António","Izaabel El Hassan"}	Genetic testing and molecular biomarkers	5	\N	\N	2017	28282224	\N	\N	\N	2	f	\N
117172	\N	Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.	{"Kamal El-Din Mennat-Allah","Farhan Marwa Salah","El Shiha Randa Ibrahim","El-Kaffas Rania Mohammed Helmy","Mousa Somaia Mohammed"}	Paediatric drugs	8	\N	\N	2014	24797541	\N	\N	\N	2	f	\N
113908	\N	Warfarin pharmacogenetics: polymorphisms of the CYP2C9, CYP4F2, and VKORC1 loci in a genetically admixed Omani population.	{"Pathare Anil V","Al Zadjali Shoaib","Misquith Rhea","Alkindi Salam S","Panjwani Vinodh","Lapoumeroulie Claudine","Pravin Sahaya","Paldi Andras","Krishnamoorthy Rajagopal"}	Human biology	2	\N	\N	2012	22452429	\N	\N	\N	2	f	\N
116645	\N	Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population.	{"Djaffar-Jureidini Isabelle","Chamseddine Nabil","Keleshian Sose","Naoufal Rania","Zahed Laila","Hakime Noha"}	Genetic testing and molecular biomarkers	11	\N	\N	2011	21651319	\N	\N	\N	2	f	\N
116649	\N	Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy.	{"Poopak Behzad","Rabieipoor Saghar","Safari Nazila","Naraghi Emadedin","Sheikhsofla Fatemeh","Khosravipoor Gelareh"}	International journal of hematology-oncology and stem cell research	10	\N	\N	2015	26865929	\N	\N	\N	2	f	\N
117187	\N	Allele frequency of CYP2C9 gene polymorphisms in Iran.	{"Peyvandi F","Spreafico M","Karimi M","Zeinali S","Mannucci P M","Bianchi Bonomi A"}	Thrombosis and haemostasis	11	\N	\N	2002	12428110	\N	\N	\N	2	f	\N
116651	\N	Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia.	{"Alzahrani Abdullah M","Ragia Georgia","Hanieh Hamza","Manolopoulos Vangelis G"}	BioMed research international	0	\N	\N	2013	23586031	\N	\N	\N	2	f	\N
116657	\N	Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.	{"Scott Stuart A","Edelmann Lisa","Kornreich Ruth","Desnick Robert J"}	American journal of human genetics	2	\N	\N	2008	18252229	\N	\N	\N	2	f	\N
117197	\N	CYP2C9 genetic variants and losartan oxidation in a Turkish population.	{"Babaoglu Melih O","Yasar Umit","Sandberg Mia","Eliasson Erik","Dahl Marja-Liisa","Kayaalp S Oguz","Bozkurt Atila"}	European journal of clinical pharmacology	7	\N	\N	2004	15197523	\N	\N	\N	2	f	\N
117199	\N	The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.	{"Dilge Taşkın Birce","Kula Serdar","Ergün Mehmet Ali","Altun Demet","Olguntürk Rana","Tunaoğlu Fatma Sedef","Oğuz Ayşe Deniz","Gürsel Türkiz"}	Anatolian journal of cardiology	10	\N	\N	2016	27182616	\N	\N	\N	2	f	\N
117210	\N	The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population.	{"Silan Coskun","Dogan Omer Tamer","Silan Fatma","Kukulguven Fatma Mutlu","Asgun Halil Fatih","Ozdemir Semra","Uludag Ahmet","Atik Sinem","Gungor Buket","Akdur Seçil","Aksulu Hakki Engin","Ozdemir Oztürk"}	Molecular biology reports	12	\N	\N	2012	23065265	\N	\N	\N	2	f	\N
117212	\N	Lower CYP2C9 activity in Turkish patients with Behçet's disease compared to healthy subjects: a down-regulation due to inflammation?	{"Goktaş Mustafa Tugrul","Hatta Fazleen","Karaca Ozgur","Kalkisim Said","Kilic Levent","Akdogan Ali","Babaoglu Melih O","Bozkurt Atilla","Helldén Anders","Bertilsson Leif","Yasar Umit"}	European journal of clinical pharmacology	10	\N	\N	2015	26233334	\N	\N	\N	2	f	\N
114806	\N	CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.	{"Scott Stuart A","Edelmann Lisa","Kornreich Ruth","Erazo Monica","Desnick Robert J"}	Pharmacogenomics	7	\N	\N	2007	18240905	\N	\N	\N	2	f	\N
117232	\N	VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals.	{"Aklillu Eleni","Leong Cheryl","Loebstein Ronen","Halkin Hillel","Gak Eva"}	Blood	4	\N	\N	2008	18362220	\N	\N	\N	2	f	\N
117238	\N	Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians.	{"Janha Ramatoulie E","Sisay-Joof Fatoumatta","Hamid-Adiamoh Majidah","Worwui Archibald","Chapman Hannah L","Opara Hyginus","Dunyo Sam","Milligan Paul","Rockett Kirk","Winstanley Peter","Pirmohamed Munir","Miller Ann K","Conway David J","Walton Robert T"}	Pharmacogenomics	9	\N	\N	2009	19761366	\N	\N	\N	2	f	\N
117241	\N	Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.	{"Kudzi William","Ahorhorlu Samuel Yao","Dzudzor Bartholomew","Olayemi Edeghonghon","Nartey Edmund Tetteh","Asmah Richard Harry"}	BMC research notes	12	\N	\N	2016	27938396	\N	\N	\N	2	f	\N
114363	\N	CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.	{"Leathart J B","London S J","Steward A","Adams J D","Idle J R","Daly A K"}	Pharmacogenetics	12	\N	\N	1998	9918137	\N	\N	\N	2	f	\N
114369	\N	Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D642, in African American subjects.	{"Gaedigk Andrea","Ndjountché Liliane","Gaedigk Roger","Leeder J Steven","Bradford L DiAnne"}	Clinical pharmacology and therapeutics	6	\N	\N	2003	12811367	\N	\N	\N	2	f	\N
114371	\N	Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans.	{"Gaedigk A","Bhathena A","Ndjountché L","Pearce R E","Abdel-Rahman S M","Alander S W","Bradford L DiAnne","Rogan P K","Leeder J Steven"}	The pharmacogenomics journal	0	\N	\N	2005	15768052	\N	\N	\N	2	f	\N
114373	\N	Limited association of the 2988g > a single nucleotide polymorphism with CYP2D641 in black subjects.	{"Gaedigk Andrea","Ndjountché Liliane","Leeder J Steven","Bradford L Dianne"}	Clinical pharmacology and therapeutics	3	\N	\N	2005	15735618	\N	\N	\N	2	f	\N
114379	\N	CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.	{"Gaedigk Andrea","Bradford L Dianne","Alander Sarah W","Leeder J Steven"}	Drug metabolism and disposition: the biological fate of chemicals	4	\N	\N	2006	16415111	\N	\N	\N	2	f	\N
114381	\N	Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events.	{"Gaedigk A","Ndjountché L","Divakaran K","Dianne Bradford L","Zineh I","Oberlander T F","Brousseau D C","McCarver D G","Johnson J A","Alander S W","Wayne Riggs K","Steven Leeder J"}	Clinical pharmacology and therapeutics	2	\N	\N	2007	17259947	\N	\N	\N	2	f	\N
114385	\N	Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype.	{"Gaedigk A","Eklund J D","Pearce R E","Leeder J S","Alander S W","Phillips M S","Bradford L D","Kennedy M J"}	Clinical pharmacology and therapeutics	6	\N	\N	2007	17392730	\N	\N	\N	2	f	\N
114391	\N	Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations.	{"Gaedigk Andrea","Isidoro-García Maria","Pearce Robin E","Sánchez Santiago","García-Solaesa Virginia","Lorenzo-Romo Carolina","Gonzalez-Tejera Gloria","Corey Susan"}	European journal of clinical pharmacology	9	\N	\N	2010	20473659	\N	\N	\N	2	f	\N
114393	\N	Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease.	{"Yee Marianne M","Josephson Cassandra","Hill Charles E","Harrington Rosiland","Castillejo Marta-Inés","Ramjit Ruan","Osunkwo Ifeyinwa"}	Journal of pediatric hematology/oncology	10	\N	\N	2013	23619115	\N	\N	\N	2	f	\N
114397	\N	CYP2D6 and CYP2C19 genotyping in psychiatric patients on psychotropic medication in the former Dutch Antilles.	{"Koopmans Anne B","Vinkers David J","Gelan Petra Ja","Hoek Hans W","van Harten Peter N"}	Pharmacogenomics	7	\N	\N	2017	28639468	\N	\N	\N	2	f	\N
114402	\N	Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans.	{"Céspedes-Garro Carolina","Jiménez-Arce Gerardo","Naranjo María-Eugenia G","Barrantes Ramiro","Llerena Adrián","CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics & Pharmacogenomics RIBEF"}	Revista de biologia tropical	12	\N	\N	2014	25720195	\N	\N	\N	2	f	\N
114495	\N	Identification of CYP2D6 impaired functional alleles in Mexican Americans.	{"Luo Huai-Rong","Gaedigk Andrea","Aloumanis Vasileios","Wan Yu-Jui Yvonne"}	European journal of clinical pharmacology	12	\N	\N	2005	16283274	\N	\N	\N	2	f	\N
114404	\N	Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.	{"Spring Michele D","Sousa Jason C","Li Qigui","Darko Christian A","Morrison Meshell N","Marcsisin Sean R","Mills Kristin T","Potter Brittney M","Paolino Kristopher M","Twomey Patrick S","Moon James E","Tosh Donna M","Cicatelli Susan B","Froude Jeffrey W","Pybus Brandon S","Oliver Thomas G","McCarthy William F","Waters Norman C","Smith Philip L","Reichard Gregory A","Bennett Jason W"}	The Journal of infectious diseases	10	\N	\N	2019	31549155	\N	\N	\N	2	f	\N
114408	\N	Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes in a Brazilian population.	{"Silveira Vanessa Da Silva","Canalle Renata","Scrideli Carlos Alberto","Queiroz Rosane Gomes de Paula","Tone Luiz Gonzaga"}	Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals	3	\N	\N	2009	19330589	\N	\N	\N	2	f	\N
114412	\N	Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.	{"Aklillu E","Persson I","Bertilsson L","Johansson I","Rodrigues F","Ingelman-Sundberg M"}	The Journal of pharmacology and experimental therapeutics	7	\N	\N	1996	8764380	\N	\N	\N	2	f	\N
114417	\N	Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.	{"Griese E U","Asante-Poku S","Ofori-Adjei D","Mikus G","Eichelbaum M"}	Pharmacogenetics	12	\N	\N	1999	10634134	\N	\N	\N	2	f	\N
114419	\N	Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa.	{"Awandu Shehu S","Raman Jaishree","Makhanthisa Takalani I","Kruger Philip","Frean John","Bousema Teun","Niemand Jandeli","Birkholtz Lyn-Marie"}	Malaria journal	3	\N	\N	2018	29558929	\N	\N	\N	2	f	\N
114428	\N	Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.	{"Wennerholm A","Johansson I","Massele A Y","Lande M","Alm C","Aden-Abdi Y","Dahl M L","Ingelman-Sundberg M","Bertilsson L","Gustafsson L L"}	Pharmacogenetics	12	\N	\N	1999	10634133	\N	\N	\N	2	f	\N
114430	\N	Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity.	{"Wennerholm A","Johansson I","Hidestrand M","Bertilsson L","Gustafsson L L","Ingelman-Sundberg M"}	Pharmacogenetics	7	\N	\N	2001	11470994	\N	\N	\N	2	f	\N
114432	\N	Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population.	{"Wright Galen E B","Niehaus Dana J H","Drögemöller Britt I","Koen Liezl","Gaedigk Andrea","Warnich Louise"}	Annals of human genetics	7	\N	\N	2010	20597905	\N	\N	\N	2	f	\N
114437	\N	Tiron protects against nicotine-induced lung and liver injury through antioxidant and anti-inflammatory actions in rats in vivo.	{"Khaled Shimaa","Makled Mirhan N","Nader Manar A"}	Life sciences	9	\N	\N	2020	32937159	\N	\N	\N	2	f	\N
114544	\N	Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population.	{"Cai W M","Chen B","Zhang W X"}	Clinical pharmacology and therapeutics	1	\N	\N	2007	17186005	\N	\N	\N	2	f	\N
114442	\N	Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.	{"Khan Burhan A","Robinson Renee","Fohner Alison E","Muzquiz LeeAnna I","Schilling Brian D","Beans Julie A","Olnes Matthew J","Trawicki Laura","Frydenlund Holly","Laukes Cindi","Beatty Patrick","Phillips Brian","Nickerson Deborah","Howlett Kevin","Dillard Denise A","Thornton Timothy A","Thummel Kenneth E","Woodahl Erica L"}	Clinical and translational science	2	\N	\N	2018	29436156	\N	\N	\N	2	f	\N
114447	\N	Allele and genotype frequencies of metabolic genes in Native Americans from Argentina and Paraguay.	{"Bailliet G","Santos M R","Alfaro E L","Dipierri J E","Demarchi D A","Carnese F R","Bianchi N O"}	Mutation research	3	\N	\N	2007	17194620	\N	\N	\N	2	f	\N
114449	\N	CYP2D6-related oxidation polymorphism in a Canadian Inuit population.	{"Jurima-Romet M","Foster B C","Casley W L","Rode A","Vloshinsky P","Huang H S","Geertsen S"}	Canadian journal of physiology and pharmacology	3	\N	\N	1997	9164697	\N	\N	\N	2	f	\N
114454	\N	Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile.	{"Muñoz S","Vollrath V","Vallejos M P","Miquel J F","Covarrubias C","Raddatz A","Chianale J"}	Pharmacogenetics	8	\N	\N	1998	9731721	\N	\N	\N	2	f	\N
114459	\N	Resequencing, haplotype construction and identification of novel variants of CYP2D6 in Mexican Mestizos.	{"Contreras Alejandra V","Monge-Cazares Tulia","Alfaro-Ruiz Luis","Hernandez-Morales Salvador","Miranda-Ortiz Haydee","Carrillo-Sanchez Karol","Jimenez-Sanchez Gerardo","Silva-Zolezzi Irma"}	Pharmacogenomics	5	\N	\N	2011	21391885	\N	\N	\N	2	f	\N
114468	\N	CYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas.	{"López-López Marisol","Peñas-Lledó Eva","Dorado Pedro","Ortega Alberto","Corona Teresa","Ochoa Adriana","Yescas Petra","Alonso Elisa","LLerena Adrián"}	Pharmacogenomics	0	\N	\N	2014	25495408	\N	\N	\N	2	f	\N
114470	\N	CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico.	{"Sosa-Macías Martha","Elizondo Guillermo","Flores-Pérez Carmen","Flores-Pérez Janet","Bradley-Alvarez Francisco","Alanis-Bañuelos Ruth E","Lares-Asseff Ismael"}	Journal of clinical pharmacology	5	\N	\N	2006	16638736	\N	\N	\N	2	f	\N
114477	\N	Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations.	{"Jorge L F","Eichelbaum M","Griese E U","Inaba T","Arias T D"}	Pharmacogenetics	4	\N	\N	1999	10376769	\N	\N	\N	2	f	\N
114480	\N	CYP2D6 gene variants in urban/admixed and Amerindian populations of Venezuela: pharmacogenetics and anthropological implications.	{"Griman Pedro","Moran Yeinmy","Valero Gabriela","Loreto Mariana","Borjas Lisbeth","Chiurillo Miguel A"}	Annals of human biology	3	\N	\N	2012	22324840	\N	\N	\N	2	f	\N
114488	\N	Allelic variants of the CYP2D6: *4, *6 and *10 in a sample of resident from the Aragua state, Venezuela.	{"Flores-Angulo Carlos","Villegas Cecilia","Mora Yuselin","Martínez José Antonio","Oropeza Teresa","Moreno Nancy"}	Revista peruana de medicina experimental y salud publica	10	\N	\N	2015	26732924	\N	\N	\N	2	f	\N
114499	\N	Polymorphisms of xenobiotic metabolizing enzymes and DNA repair genes and outcome in childhood acute lymphoblastic leukemia.	{"da Silva Silveira Vanessa","Canalle Renata","Scrideli Carlos Alberto","Queiroz Rosane Gomes de Paula","Bettiol Heloisa","Valera Elvis Terci","Tone Luiz Gonzaga"}	Leukemia research	7	\N	\N	2009	19162321	\N	\N	\N	2	f	\N
114502	\N	Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.	{"Antunes Marina V","Linden Rafael","Santos Tamyris V","Wallemacq Pierre","Haufroid Vincent","Classen Jean-François","Andreolla Huander","Costa Nathalia","Fontanive Tiago O","Rosa Daniela D"}	Therapeutic drug monitoring	8	\N	\N	2012	22777153	\N	\N	\N	2	f	\N
114504	\N	Distribution of CYP2D6 alleles and phenotypes in the Brazilian population.	{"Friedrich Deise C","Genro Júlia P","Sortica Vinicius A","Suarez-Kurtz Guilherme","de Moraes Maria Elizabete","Pena Sergio D J","dos Santos Andrea K Ribeiro","Romano-Silva Marco A","Hutz Mara H"}	PloS one	0	\N	\N	2014	25329392	\N	\N	\N	2	f	\N
114508	\N	Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses.	{"Varela Nelson","Quiñones Luis A","Stojanova Jana","Garay Joselyn","Cáceres Dante","Cespedes Silvia","Sasso Jaime","Miranda Carla"}	Pharmacological research	11	\N	\N	2015	26211952	\N	\N	\N	2	f	\N
114513	\N	Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population.	{"Isaza C A","Henao J","López A M","Cacabelos R"}	Methods and findings in experimental and clinical pharmacology	11	\N	\N	2000	11294012	\N	\N	\N	2	f	\N
114517	\N	CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.	{"Llerena A","Dorado P","Ramírez R","González I","Alvarez M","Peñas-Lledó E M","Pérez B","Calzadilla L R"}	The pharmacogenomics journal	4	\N	\N	2012	21135868	\N	\N	\N	2	f	\N
114519	\N	Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.	{"Dorado Pedro","González Idilio","Naranjo María Eugenia G","de Andrés Fernando","Peñas-Lledó Eva María","Calzadilla Luis Ramón","LLerena Adrián"}	Omics : a journal of integrative biology	1	\N	\N	2017	28271978	\N	\N	\N	2	f	\N
114523	\N	CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.	{"López Marisol","Guerrero Jorge","Jung-Cook Helgi","Alonso María Elisa"}	European journal of clinical pharmacology	11	\N	\N	2005	16249913	\N	\N	\N	2	f	\N
114533	\N	Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH.	{"Roehrborn C G","Kaplan S A","Lepor H","Volinn W"}	Prostate cancer and prostatic diseases	6	\N	\N	2011	21135869	\N	\N	\N	2	f	\N
114535	\N	Physiogenomic analysis of the Puerto Rican population.	{"Ruaño Gualberto","Duconge Jorge","Windemuth Andreas","Cadilla Carmen L","Kocherla Mohan","Villagra David","Renta Jessica","Holford Theodore","Santiago-Borrero Pedro J"}	Pharmacogenomics	4	\N	\N	2009	19374515	\N	\N	\N	2	f	\N
114546	\N	Allelic distributions of CYP2D6 gene copy number variation in the Eastern Han Chinese population.	{"Sheng Hai-hui","Zeng Ai-ping","Zhu Wen-xiang","Zhu Ren-fang","Li Hong-mei","Zhu Zhi-dong","Qin Ying","Jin Wei","Liu Yan","Du Yun-lan","Sun Jian","Xiao Hua-sheng"}	Acta pharmacologica Sinica	2	\N	\N	2007	17241532	\N	\N	\N	2	f	\N
114556	\N	Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations.	{"Kim Eun-Young","Lee Sang-Seop","Jung Hyun-Ju","Jung Hye-Eun","Yeo Chang-Woo","Shon Ji-Hong","Shin Jae-Gook"}	Clinica chimica acta; international journal of clinical chemistry	12	\N	\N	2010	20828547	\N	\N	\N	2	f	\N
114563	\N	Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia.	{"Li Juyi","Wang Xiufang","Zhang Zhaoqing","Zou Jili","Chen Yonggang","Wang Xiong","Wu Jinhu"}	Current medical research and opinion	2	\N	\N	2014	24156754	\N	\N	\N	2	f	\N
114565	\N	Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment.	{"Yi SoJeong","An Hyungmi","Lee Howard","Lee Sangin","Ieiri Ichiro","Lee Youngjo","Cho Joo-Youn","Hirota Takeshi","Fukae Masato","Yoshida Kenji","Nagatsuka Shinichiro","Kimura Miyuki","Irie Shin","Sugiyama Yuichi","Shin Dong Wan","Lim Kyoung Soo","Chung Jae-Yong","Yu Kyung-Sang","Jang In-Jin"}	Pharmacogenetics and genomics	10	\N	\N	2014	25029633	\N	\N	\N	2	f	\N
114572	\N	Genetic variations of human CYP2D6 in the Chinese Han population.	{"Qian Jian-Chang","Xu Xin-Min","Hu Guo-Xin","Dai Da-Peng","Xu Ren-Ai","Hu Li-Ming","Li Fang-Hong","Zhang Xiu-Hua","Yang Jie-Fu","Cai Jian-Ping"}	Pharmacogenomics	11	\N	\N	2013	24192122	\N	\N	\N	2	f	\N
114578	\N	CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer.	{"Love Richard R","Desta Zuerenesay","Flockhart David","Skaar Todd","Ogburn Evan T","Ramamoorthy Anuradha","Uy Gemma B","Laudico Adriano V","Van Dinh Nguyen","Quang Le Hong","Van To Ta","Young Gregory S","Hade Erinn","Jarjoura David"}	SpringerPlus	12	\N	\N	2013	23476897	\N	\N	\N	2	f	\N
114582	\N	Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population.	{"Tateishi T","Chida M","Ariyoshi N","Mizorogi Y","Kamataki T","Kobayashi S"}	Clinical pharmacology and therapeutics	5	\N	\N	1999	10340923	\N	\N	\N	2	f	\N
114584	\N	Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.	{"Kubota T","Yamaura Y","Ohkawa N","Hara H","Chiba K"}	British journal of clinical pharmacology	7	\N	\N	2000	10886115	\N	\N	\N	2	f	\N
114588	\N	New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine.	{"Chida Michihiro","Ariyoshi Noritaka","Yokoi Tsuyoshi","Nemoto Nobuo","Inaba Makoto","Kinoshita Moritoshi","Kamataki Tetsuya"}	Pharmacogenetics	11	\N	\N	2002	12439227	\N	\N	\N	2	f	\N
114592	\N	Two novel haplotypes of CYP2D6 gene in a Japanese population.	{"Yamazaki Hiroshi","Kiyotani Kazuma","Tsubuko Satoshi","Matsunaga Masayuki","Fujieda Masaki","Saito Tetsuya","Miura Jun","Kobayashi Shinichi","Kamataki Tetsuya"}	Drug metabolism and pharmacokinetics	0	\N	\N	2003	15618746	\N	\N	\N	2	f	\N
114594	\N	Novel nonsynonymous single nucleotide polymorphisms in the CYP2D6 gene.	{"Soyama Akiko","Kubo Takashi","Miyajima Atsuko","Saito Yoshiro","Shiseki Kisho","Komamura Kazuo","Ueno Kazuyuki","Kamakura Shiro","Kitakaze Masafumi","Tomoike Hitonobu","Ozawa Shogo","Sawada Jun-ichi"}	Drug metabolism and pharmacokinetics	8	\N	\N	2004	15499201	\N	\N	\N	2	f	\N
114598	\N	The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution.	{"Ikenaga Yuka","Fukuda Tsuyoshi","Fukuda Kazuhiro","Nishida Yuko","Naohara Masakazu","Maune Hiromi","Azuma Junichi"}	Drug metabolism and pharmacokinetics	4	\N	\N	2005	15855722	\N	\N	\N	2	f	\N
114603	\N	CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection.	{"Hosono Naoya","Kato Mamoru","Kiyotani Kazuma","Mushiroda Taisei","Takata Sadaaki","Sato Hiroko","Amitani Hanae","Tsuchiya Yumiko","Yamazaki Keiko","Tsunoda Tatsuhiko","Zembutsu Hitoshi","Nakamura Yusuke","Kubo Michiaki"}	Clinical chemistry	8	\N	\N	2009	19541866	\N	\N	\N	2	f	\N
114605	\N	Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population.	{"Kiyotani Kazuma","Shimizu Makiko","Kumai Toshio","Kamataki Tetsuya","Kobayashi Shinichi","Yamazaki Hiroshi"}	European journal of clinical pharmacology	10	\N	\N	2010	20700584	\N	\N	\N	2	f	\N
114607	\N	Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.	{"Kiyotani Kazuma","Mushiroda Taisei","Imamura Chiyo K","Hosono Naoya","Tsunoda Tatsuhiko","Kubo Michiaki","Tanigawara Yusuke","Flockhart David A","Desta Zeruesenay","Skaar Todd C","Aki Fuminori","Hirata Koichi","Takatsuka Yuichi","Okazaki Minoru","Ohsumi Shozo","Yamakawa Takashi","Sasa Mitsunori","Nakamura Yusuke","Zembutsu Hitoshi"}	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	3	\N	\N	2010	20124171	\N	\N	\N	2	f	\N
114615	\N	Association between cytochrome P450 2D6 polymorphisms and body fluid methamphetamine concentrations in Japanese forensic autopsy cases.	{"Matsusue Aya","Ikeda Tomoya","Tani Naoto","Waters Brian","Hara Kenji","Kashiwagi Masayuki","Takayama Mio","Ikematsu Natsuki","Kubo Shin-Ichi","Ishikawa Takaki"}	Forensic science international	8	\N	\N	2018	29843110	\N	\N	\N	2	f	\N
114618	\N	Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study.	{"Puaprasert Kanokpich","Chu Cindy","Saralamba Naowarat","Day Nicholas P J","Nosten Francois","White Nicholas J","Dondorp Arjen M","Imwong Mallika"}	Malaria journal	11	\N	\N	2018	30442143	\N	\N	\N	2	f	\N
114623	\N	Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans.	{"Lee Su-Jun","Lee Sang Seop","Jung Hyun-Ju","Kim Ho-Sook","Park Soo-Jin","Yeo Chang-Woo","Shin Jae-Gook"}	Drug metabolism and disposition: the biological fate of chemicals	7	\N	\N	2009	19364831	\N	\N	\N	2	f	\N
114815	\N	Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3, *4, and *6) within an Iranian population (Mazandaran).	{"Hashemi-Soteh Seyed Mohammad Bagher","Sarzare Fatemeh","Merat Fatemeh","Salehifar Ebrahim","Shiran Mohammad-Reza"}	Genetic testing and molecular biomarkers	11	\N	\N	2011	21631295	\N	\N	\N	2	f	\N
114630	\N	CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.	{"Byeon Ji-Young","Kim Young-Hoon","Lee Choong-Min","Kim Se-Hyung","Chae Won-Ki","Jung Eui-Hyun","Choi Chang-Ik","Jang Choon-Gon","Lee Seok-Yong","Bae Jung-Woo","Lee Yun Jeong"}	Archives of pharmacal research	9	\N	\N	2018	30191460	\N	\N	\N	2	f	\N
114632	\N	Heterogeneity of the CYP2D6 gene among Malays in Malaysia.	{"Teh L K","Ismail R","Yusoff R","Hussein A","Isa M N","Rahman A R"}	Journal of clinical pharmacy and therapeutics	6	\N	\N	2001	11422605	\N	\N	\N	2	f	\N
114641	\N	Combination of multiplex PCR and DHPLC-based strategy for CYP2D6 genotyping scheme in Thais.	{"Suwannasri Payiarat","Thongnoppakhun Wanna","Pramyothin Pornpen","Assawamakin Anunchai","Limwongse Chanin"}	Clinical biochemistry	9	\N	\N	2011	21763299	\N	\N	\N	2	f	\N
114643	\N	Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen.	{"Chamnanphon Montri","Pechatanan Khunthong","Sirachainan Ekapob","Trachu Narumol","Chantratita Wasun","Pasomsub Ekawat","Noonpakdee Wilai","Sensorn Insee","Sukasem Chonlaphat"}	Pharmacogenomics and personalized medicine	0	\N	\N	2013	23776391	\N	\N	\N	2	f	\N
312209	\N	Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations.	{"Jittikoon Jiraphun","Mahasirimongkol Surakameth","Charoenyingwattana Angkana","Chaikledkaew Usa","Tragulpiankit Pramote","Mangmool Supachoke","Inunchot Wimala","Somboonyosdes Chayapol","Wichukchinda Nuanjun","Sawanpanyalert Pathom","He Yijing","McLeod Howard L","Chantratita Wasun"}	Journal of human genetics	2	\N	\N	2016	26423926	\N	\N	\N	2	f	\N
114647	\N	Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels.	{"Vanwong Natchaya","Ngamsamut Nattawat","Hongkaew Yaowaluck","Nuntamool Nopphadol","Puangpetch Apichaya","Chamnanphon Montri","Sinrachatanant Ananya","Limsila Penkhae","Sukasem Chonlaphat"}	Drug metabolism and pharmacokinetics	4	\N	\N	2016	26944100	\N	\N	\N	2	f	\N
114649	\N	Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder.	{"Vanwong Natchaya","Ngamsamut Nattawat","Medhasi Sadeep","Puangpetch Apichaya","Chamnanphon Montri","Tan-Kam Teerarat","Hongkaew Yaowaluck","Limsila Penkhae","Sukasem Chonlaphat"}	Journal of child and adolescent psychopharmacology	3	\N	\N	2017	26780783	\N	\N	\N	2	f	\N
114653	\N	Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population.	{"Jin Tian-Bo","Ma Li-Feng","Zhang Jia-Yi","Yuan Dong-Ya","Sun Qiang","Zong Ting-Yong","Geng Ting-Ting","Cui Ya-Li","Kang Long-Li","Chen Chao"}	Gene	9	\N	\N	2013	23644254	\N	\N	\N	2	f	\N
114662	\N	CYP2D6 allele distribution in Macedonians, Albanians and Romanies in the Republic of Macedonia.	{"Kuzmanovska M","Dimishkovska M","Maleva Kostovska I","Noveski P","Sukarova Stefanovska E","Plaseska-Karanfilska D"}	Balkan journal of medical genetics : BJMG	12	\N	\N	2015	27785397	\N	\N	\N	2	f	\N
114664	\N	CYP2D6 genotyping by liquid chromatography-electrospray ionization mass spectrometry.	{"Beer Beate","Erb Robert","Pitterl Florian","Niederstätter Harald","Maroñas Olalla","Gesteira Alejandro","Carracedo Angel","Piatkov Irina","Oberacher Herbert"}	Analytical and bioanalytical chemistry	6	\N	\N	2011	21225252	\N	\N	\N	2	f	\N
114670	\N	New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes.	{"Li Li","Pan Run-Mei","Porter Todd D","Jensen Neil S","Silber Paul","Russo Guy","Tine John A","Heim John","Ring Barbara","Wedlund Peter J"}	Drug metabolism and disposition: the biological fate of chemicals	8	\N	\N	2006	16679388	\N	\N	\N	2	f	\N
114681	\N	Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.	{"Pedersen Rasmus Steen","Damkier Per","Brosen Kim"}	Clinical pharmacology and therapeutics	6	\N	\N	2005	15961977	\N	\N	\N	2	f	\N
114683	\N	CYP2D6 gene test in psychiatric patients and healthy volunteers.	{"Rasmussen J O","Christensen M","Svendsen J M","Skausig O","Hansen E L","Nielsen K A"}	Scandinavian journal of clinical and laboratory investigation	0	\N	\N	2006	16537246	\N	\N	\N	2	f	\N
114695	\N	Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.	{"Sistonen Johanna","Fuselli Silvia","Palo Jukka U","Chauhan Neelam","Padh Harish","Sajantila Antti"}	Pharmacogenetics and genomics	2	\N	\N	2009	19151603	\N	\N	\N	2	f	\N
114700	\N	Completed suicides of citalopram users-the role of CYP genotypes and adverse drug interactions.	{"Rahikainen Anna-Liina","Vauhkonen P","Pett H","Palo J U","Haukka J","Ojanperä I","Niemi M","Sajantila Antti"}	International journal of legal medicine	3	\N	\N	2019	30173302	\N	\N	\N	2	f	\N
114703	\N	Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.	{"Marez D","Legrand M","Sabbagh N","Lo Guidice J M","Spire C","Lafitte J J","Meyer U A","Broly F"}	Pharmacogenetics	6	\N	\N	1997	9241659	\N	\N	\N	2	f	\N
114707	\N	Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.	{"Griese E U","Zanger U M","Brudermanns U","Gaedigk A","Mikus G","Mörike K","Stüven T","Eichelbaum M"}	Pharmacogenetics	2	\N	\N	1998	9511177	\N	\N	\N	2	f	\N
114709	\N	A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.	{"Raimundo Sebastian","Toscano Claudia","Klein Kathrin","Fischer Joachim","Griese Ernst-Ulrich","Eichelbaum Michel","Schwab Matthias","Zanger Ulrich M"}	Clinical pharmacology and therapeutics	8	\N	\N	2004	15289790	\N	\N	\N	2	f	\N
114716	\N	Increased prevalence of functional minor allele variants of drug metabolizing CYP2B6 and CYP2D6 genes in Roma population samples.	{"Weber Agnes","Szalai Renata","Sipeky Csilla","Magyari Lili","Melegh Marton","Jaromi Luca","Matyas Petra","Duga Balazs","Kovesdi Erzsebet","Hadzsiev Kinga","Melegh Bela"}	Pharmacological reports : PR	6	\N	\N	2015	25933954	\N	\N	\N	2	f	\N
114718	\N	Patients with difficult-to-treat depression do not exhibit an increased frequency of CYP2D6 allele duplication.	{"Háber A","Rideg O","Osváth P","Fekete S","Szücs F","Fittler A","Kovács G L","Miseta A","Botz L"}	Pharmacopsychiatry	6	\N	\N	2013	23737191	\N	\N	\N	2	f	\N
114722	\N	Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes.	{"De Luca Chiara","Scordo Maria G","Cesareo Eleonora","Pastore Saveria","Mariani Serena","Maiani Gianluca","Stancato Andrea","Loreti Beatrice","Valacchi Giuseppe","Lubrano Carla","Raskovic Desanka","De Padova Luigia","Genovesi Giuseppe","Korkina Liudmila G"}	Toxicology and applied pharmacology	11	\N	\N	2010	20430047	\N	\N	\N	2	f	\N
114731	\N	CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort.	{"Dagostino Concetta","Allegri Massimo","Napolioni Valerio","D'Agnelli Simona","Bignami Elena","Mutti Antonio","van Schaik Ron Hn"}	Pharmacogenomics and personalized medicine	0	\N	\N	2018	30425549	\N	\N	\N	2	f	\N
114733	\N	Distribution of the most Common Genetic Variants Associated with a Variable Drug Response in the Population of the Republic of Macedonia.	{"Kapedanovska Nestorovska A","Jakovski K","Naumovska Z","Hiljadnikova Bajro M","Sterjev Z","Eftimov A","Matevska Geskovska N","Suturkova L","Dimitrovski K","Labacevski N","Dimovski A J"}	Balkan journal of medical genetics : BJMG	12	\N	\N	2014	25937793	\N	\N	\N	2	f	\N
114746	\N	The association of CYP2D6 genotype and postoperative nausea and vomiting in orthopedic trauma patients.	{"Wesmiller Susan W","Henker Richard A","Sereika Susan M","Donovan Heidi S","Meng Li","Gruen Gary S","Tarkin Ivan S","Conley Yvette P"}	Biological research for nursing	10	\N	\N	2013	22718526	\N	\N	\N	2	f	\N
114751	\N	Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype.	{"Molden Espen","Johansen Per Wiik","Bøe Grethe Helen","Bergan Stein","Christensen Hege","Rugstad Hans Erik","Rootwelt Helge","Reubsaet Leon","Lehne Gustav"}	Clinical pharmacology and therapeutics	9	\N	\N	2002	12235455	\N	\N	\N	2	f	\N
114753	\N	Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.	{"Gjerde J","Hauglid M","Breilid H","Lundgren S","Varhaug J E","Kisanga E R","Mellgren G","Steen V M","Lien E A"}	Annals of oncology : official journal of the European Society for Medical Oncology	1	\N	\N	2008	17947222	\N	\N	\N	2	f	\N
114757	\N	Characterization of pharmacogenetically relevant CYP2D6 and ABCB1 gene polymorphisms in a Portuguese population sample.	{"Correia C","Santos P","Coutinho A M","Vicente A M"}	Cell biochemistry and function	6	\N	\N	2009	19405050	\N	\N	\N	2	f	\N
312282	\N	Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications.	{"Albuquerque José","Ribeiro Carolina","Naranjo Maria Eugenia G","Llerena Adrián","Grazina Manuela","CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics & Pharmacogenomics RIBEF §"}	Personalized medicine	9	\N	\N	2013	29768760	\N	\N	\N	2	f	\N
114769	\N	Effect of genotype and methylation of CYP2D6 on smoking behaviour.	{"Tiili Emmi M","Antikainen Miia S H","Mitiushkina Natalia V","Sukhovskaya Olga A","Imyanitov Evgeny N","Hirvonen Ari P"}	Pharmacogenetics and genomics	11	\N	\N	2015	26287939	\N	\N	\N	2	f	\N
114771	\N	Molecular diversity at the CYP2D6 locus in the Mediterranean region.	{"Fuselli Silvia","Dupanloup Isabelle","Frigato Elena","Cruciani Fulvio","Scozzari Rosaria","Moral Pedro","Sistonen Johanna","Sajantila Antti","Barbujani Guido"}	European journal of human genetics : EJHG	11	\N	\N	2004	15340360	\N	\N	\N	2	f	\N
114776	\N	Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.	{"Crescenti A","Mas S","Gassó P","Baiget M","Bernardo M","Lafuente A"}	Clinical and experimental pharmacology & physiology	10	\N	\N	2007	17714084	\N	\N	\N	2	f	\N
114778	\N	Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.	{"Crescenti Anna","Mas Sergi","Gassó Patricia","Parellada Eduard","Bernardo Miquel","Lafuente Amalia"}	Clinical and experimental pharmacology & physiology	7	\N	\N	2008	18346175	\N	\N	\N	2	f	\N
114781	\N	CYP2D6 polymorphism screening in a selected population of Spain (La Alpujarra): no effect of geographical isolation.	{"Fernández-Santander Ana","Luna Francisco","Santiago Catalina","Rodríguez María Teresa","Bandrés Fernando","Ruiz Jonatan R","Lucia Alejandro","Gómez-Gallego Félix"}	Annals of human biology	4	\N	\N	2010	20205348	\N	\N	\N	2	f	\N
114787	\N	Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.	{"Zafra-Ceres Mercedes","de Haro Tomas","Farez-Vidal Esther","Blancas Isabel","Bandres Fernando","de Dueñas Eduardo Martinez","Ochoa-Aranda Enrique","Gomez-Capilla Jose A","Gomez-Llorente Carolina"}	International journal of medical sciences	0	\N	\N	2013	23781139	\N	\N	\N	2	f	\N
114789	\N	Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients.	{"Mas Sergi","Gassó Patricia","Torra Mercé","Bioque Miquel","Lobo Antonio","González-Pinto Ana","Olmeda Maria Soledad","Corripio Iluminada","Vieta Eduard","Castro-Fornieles Josefina","Rodriguez-Jimenez Roberto","Bobes Julio","Usall Judith","Llerena Adrián","Saiz-Ruiz Jerónimo","Bernardo Miguel","Lafuente Amalia","PEPs Group"}	European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology	7	\N	\N	2017	28389049	\N	\N	\N	2	f	\N
114791	\N	Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.	{"Belmonte Carmen","Ochoa Dolores","Román Manuel","Saiz-Rodríguez Miriam","Wojnicz Aneta","Gómez-Sánchez Clara Isabel","Martín-Vílchez Samuel","Abad-Santos Francisco"}	Basic & clinical pharmacology & toxicology	6	\N	\N	2018	29325225	\N	\N	\N	2	f	\N
114800	\N	The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.	{"Rebsamen M C","Desmeules J","Daali Y","Chiappe A","Diemand A","Rey C","Chabert J","Dayer P","Hochstrasser D","Rossier M F"}	The pharmacogenomics journal	2	\N	\N	2009	18591960	\N	\N	\N	2	f	\N
114813	\N	Frequency of five important CYP2D6 alleles within an Iranian population (Eastern Azerbaijan).	{"Kouhi Hamed","Hamzeiy Hossein","Barar Jaleh","Asadi Masoud","Omidi Yadollah"}	Genetic testing and molecular biomarkers	10	\N	\N	2009	19715474	\N	\N	\N	2	f	\N
114063	\N	Frequencies of CYP3A5 genotypes and haplotypes in a Korean population.	{"Park S Y","Kang Y S","Jeong M S","Yoon H K","Han K O"}	Journal of clinical pharmacy and therapeutics	2	\N	\N	2008	18211618	\N	\N	\N	2	f	\N
114820	\N	High prevalence of CYP2D6*41 (G2988A) allele in Saudi Arabians.	{"Al-Dosari Mohammed S","Al-Jenoobi Fahad I","Alkharfy Khalid M","Alghamdi Amal M","Bagulb Khawla M","Parvez Mohammad K","Al-Mohizea Abdullah M","Al-Muhsen Saleh","Halwani Rabih"}	Environmental toxicology and pharmacology	11	\N	\N	2013	24121619	\N	\N	\N	2	f	\N
114827	\N	Frequency of mutated allele CYP2D6*4 in the Turkish population.	{"Koseler Aylin","Ilcol Yesim Ozarda","Ulus Ismail H"}	Pharmacology	0	\N	\N	2007	17374963	\N	\N	\N	2	f	\N
114831	\N	The frequencies of mutated alleles of CYP2D6 gene in a Turkish population.	{"Serin A","Canan H","Alper B","Gulmen M"}	Forensic science international	10	\N	\N	2012	22910059	\N	\N	\N	2	f	\N
114833	\N	Correlation of CYP2D6 allelic polymorphism to outcome of acute coronary syndrome in mid-Euphrates Iraqi patients on metoprolol therapy.	{"Swadi Asma A","Mohammad Bassim I","Hadi Najah R","Al-Aubaidy Hayder A"}	Gene	6	\N	\N	2019	30965129	\N	\N	\N	2	f	\N
114835	\N	Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites.	{"Khalaj Zahra","Baratieh Zohreh","Nikpour Parvaneh","Schwab Matthias","Schaeffeler Elke","Mokarian Fariborz","Khanahmad Hossein","Salehi Rasoul","Mürdter Thomas E","Salehi Mansoor"}	Frontiers in pharmacology	0	\N	\N	2019	31178724	\N	\N	\N	2	f	\N
114844	\N	CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess.	{"von Ahsen Nicolas","Tzvetkov Mladen","Karunajeewa Harin A","Gomorrai Servina","Ura Alice","Brockmöller Jürgen","Davis Timothy M E","Mueller Ivo","Ilett Kenneth F","Oellerich Michael"}	International journal of molecular epidemiology and genetics	8	\N	\N	2010	21532842	\N	\N	\N	2	f	\N
114851	\N	Polymorphisms at CYP and GST gene loci. Prevalence in the Indian population.	{"Buch S","Kotekar A","Kawle D","Bhisey R"}	European journal of clinical pharmacology	9	\N	\N	2001	11699625	\N	\N	\N	2	f	\N
114853	\N	Genetic polymorphism of CYP2D6: Malaysian Indians have the highest frequency for CYP2D6*4 in Asia.	{"Ismail R","Teh L K"}	European journal of clinical pharmacology	10	\N	\N	2001	11758642	\N	\N	\N	2	f	\N
114855	\N	CYP2D6 genetic polymorphism in South Indian populations.	{"Naveen Amrithraj Theophilus","Adithan Chandrasekaran","Soya Sisy Sam","Gerard Nathalie","Krishnamoorthy Rajagopal"}	Biological & pharmaceutical bulletin	8	\N	\N	2006	16880622	\N	\N	\N	2	f	\N
114863	\N	Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease.	{"Singh Madhu","Khanna Vinay K","Shukla Rakesh","Parmar Devendra"}	Disease markers	0	\N	\N	2010	20364044	\N	\N	\N	2	f	\N
114865	\N	Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.	{"Damodaran Solai Elango","Pradhan Suresh Chandra","Umamaheswaran Gurusamy","Kadambari Dharanipragada","Reddy K Sathyanarayana","Adithan Chandrasekaran"}	Cancer chemotherapy and pharmacology	7	\N	\N	2012	22623212	\N	\N	\N	2	f	\N
114870	\N	Gene variants of CYP1A1 and CYP2D6 and the risk of childhood acute lymphoblastic leukaemia; outcome of a case control study from Kashmir, India.	{"Nida Sadiq","Javid Bhat","Akbar Masood","Idrees Shah","Adil Wani","Ahmad Ganai Bashir"}	Molecular biology research communications	6	\N	\N	2017	28775993	\N	\N	\N	2	f	\N
114872	\N	Distribution of CYP2D6 genotypes in the Indian population - preliminary report.	{"Paradkar Minal U","Shah Swarup A V","Dherai Alpa J","Shetty Dhanashri","Ashavaid Tester F"}	Drug metabolism and personalized therapy	9	\N	\N	2018	30098281	\N	\N	\N	2	f	\N
114876	\N	Further evidence for the association of CYP2D6*4 gene polymorphism with Parkinson's disease: a case control study.	{Anwarullah,"Aslam Muhammad","Badshah Mazhar","Abbasi Rashda","Sultan Aneesa","Khan Kafaitullah","Ahmad Nafees","von Engelhardt Jakob"}	Genes and environment : the official journal of the Japanese Environmental Mutagen Society	0	\N	\N	2017	28680508	\N	\N	\N	2	f	\N
114880	\N	Resequencing CYP2D6 gene in Indian population: CYP2D6*41 identified as the major reduced function allele.	{"Manoharan Aarthi","Shewade Deepak Gopal","Ravindranath Pradeep Anand","Rajkumar Ravi Philip","Ramprasad Vedam L","Adithan Surendiran","Damodaran Solai Elango"}	Pharmacogenomics	7	\N	\N	2019	31368850	\N	\N	\N	2	f	\N
113921	\N	Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.	{"Jacobson Pamala A","Oetting William S","Brearley Ann M","Leduc Robert","Guan Weihau","Schladt David","Matas Arthur J","Lamba Vishal","Julian Bruce A","Mannon Rosalyn B","Israni Ajay","DeKAF Investigators"}	Transplantation	2	\N	\N	2011	21206424	\N	\N	\N	2	f	\N
113923	\N	CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.	{"Givens Raymond C","Lin Yvonne S","Dowling Amy L S","Thummel Kenneth E","Lamba Jatinder K","Schuetz Erin G","Stewart Paul W","Watkins Paul B"}	Journal of applied physiology (Bethesda, Md. : 1985)	9	\N	\N	2003	12754175	\N	\N	\N	2	f	\N
113927	\N	Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms.	{"Aquilante Christina L","Langaee Taimour Y","Anderson Peter L","Zineh Issam","Fletcher Courtney V"}	Clinica chimica acta; international journal of clinical chemistry	10	\N	\N	2006	16701601	\N	\N	\N	2	f	\N
113929	\N	Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.	{"Kuehl P","Zhang J","Lin Y","Lamba J","Assem M","Schuetz J","Watkins P B","Daly A","Wrighton S A","Hall S D","Maurel P","Relling M","Brimer C","Yasuda K","Venkataramanan R","Strom S","Thummel K","Boguski M S","Schuetz E"}	Nature genetics	4	\N	\N	2001	11279519	\N	\N	\N	2	f	\N
113931	\N	An integrated map of genetic variation from 1,092 human genomes.	{"1000 Genomes Project Consortium","Abecasis Goncalo R","Auton Adam","Brooks Lisa D","DePristo Mark A","Durbin Richard M","Handsaker Robert E","Kang Hyun Min","Marth Gabor T","McVean Gil A"}	Nature	11	\N	\N	2012	23128226	\N	\N	\N	2	f	\N
113937	\N	Genotypes and phenotypes of CYP3A in Bangladeshi population.	{"Al Maruf Abdullah","Ahmed Maizbha Uddin","Yasmin Hasina","Ullah Md Ashik","Azad M A K","Daly Ann K","Hasnat Abul"}	Clinica chimica acta; international journal of clinical chemistry	3	\N	\N	2011	21114969	\N	\N	\N	2	f	\N
113939	\N	Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population.	{"Islam Mohammad Safiqul","Mostofa A G M","Ahmed Maizbha Uddin","Bin Sayeed Muhammad Shahdaat","Hassan Md Rajib","Hasnat Abul"}	Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine	2	\N	\N	2014	24085358	\N	\N	\N	2	f	\N
113943	\N	Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population.	{"Krishnakumar D","Gurusamy Umamaheswaran","Dhandapani Kayathri","Surendiran A","Baghel Ruchi","Kukreti Ritushree","Gangadhar Reneega","Prayaga Ushakiran","Manjunath S","Adithan C"}	Fundamental & clinical pharmacology	4	\N	\N	2012	21265876	\N	\N	\N	2	f	\N
113948	\N	Genetic polymorphism of CYP3A5 in Indian chronic myeloid leukemia patients.	{"Bajpai Prachi","Tripathi Anil Kumar","Agrawal Deepa"}	Molecular and cellular biochemistry	3	\N	\N	2010	19823770	\N	\N	\N	2	f	\N
113950	\N	Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups.	{"Li D","Zhang G-L","Lou Y-Q","Li Q","Wang X","Bu X-Y"}	Journal of clinical pharmacy and therapeutics	2	\N	\N	2007	17286792	\N	\N	\N	2	f	\N
113955	\N	Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.	{"Liu Chin-Hung","Peck Konan","Huang Jin-Ding","Lin Min-Shung","Wang Chin-Hsiung","Hsu Wen-Pin","Wang Hong-Wen","Lee Hui-Ling","Lai Ming-Liang"}	Pharmacogenomics	10	\N	\N	2005	16207150	\N	\N	\N	2	f	\N
113960	\N	CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients.	{"Xue Feng","Han Longzhi","Chen Yikuan","Xi Zhifeng","Li Qigen","Xu Ning","Xia Yun","Streicher Katie","Zhang Jianjun","Xia Qiang"}	Pediatric transplantation	3	\N	\N	2014	24438215	\N	\N	\N	2	f	\N
113962	\N	Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine.	{"Zuo Xiao-cong","Zhou Ya-nan","Zhang Bi-kui","Yang Guo-ping","Cheng Ze-neng","Yuan Hong","Ouyang Dong-sheng","Liu Shi-kun","Barrett Jeffrey S","Li Pei-jiong","Liu Zhi","Tan Hong-yi","Guo Ren","Zhou Ling-yun","Xie Yue-liang","Li Zuo-jun","Li Jing","Wang Chun-jiang","Wang Jiang-lin"}	Drug metabolism and pharmacokinetics	0	\N	\N	2013	23438946	\N	\N	\N	2	f	\N
113966	\N	Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.	{"Zhao Y","Song M","Guan D","Bi S","Meng J","Li Q","Wang W"}	Transplantation proceedings	0	\N	\N	2005	15808586	\N	\N	\N	2	f	\N
113968	\N	CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.	{"Li Dan-ying","Teng Rui-chen","Zhu Huai-jun","Fang Yun"}	International journal of clinical pharmacology and therapeutics	6	\N	\N	2013	23557867	\N	\N	\N	2	f	\N
113970	\N	Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.	{"Zuo Xiao-cong","Ng Chee M","Barrett Jeffrey S","Luo Ai-jing","Zhang Bi-kui","Deng Chen-hui","Xi Lan-yan","Cheng Ke","Ming Ying-zi","Yang Guo-ping","Pei Qi","Zhu Li-jun","Yuan Hong","Liao Hai-qiang","Ding Jun-jie","Wu Di","Zhou Ya-nan","Jing Ning-ning","Huang Zhi-jun"}	Pharmacogenetics and genomics	5	\N	\N	2013	23459029	\N	\N	\N	2	f	\N
113974	\N	Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.	{"Shi X-J","Geng F","Jiao Z","Cui X-Y","Qiu X-Y","Zhong M-K"}	Journal of clinical pharmacy and therapeutics	10	\N	\N	2011	21916909	\N	\N	\N	2	f	\N
113976	\N	Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period.	{"Zhang Xiaoqing","Wang Zhaowen","Fan Junwei","Liu Gaolin","Peng Zhihai"}	European journal of clinical pharmacology	8	\N	\N	2011	21359536	\N	\N	\N	2	f	\N
113980	\N	Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.	{"Rong G","Jing L","Deng-Qing L","Hong-Shan Z","Shai-Hong Z","Xin-Min N"}	Transplantation proceedings	11	\N	\N	2010	21094796	\N	\N	\N	2	f	\N
113982	\N	Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients.	{"Li Chuan-Jiang","Li Liang","Lin Li","Jiang Hai-Xia","Zhong Ze-Yan","Li Wei-Mo","Zhang Yan-Jun","Zheng Ping","Tan Xu-Hui","Zhou Lin"}	PloS one	0	\N	\N	2014	24465960	\N	\N	\N	2	f	\N
113986	\N	Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus.	{"Li Dan","Zhu Ji-Ye","Gao Jie","Wang Xin","Lou Ya-Qing","Zhang Guo-Liang"}	Clinica chimica acta; international journal of clinical chemistry	8	\N	\N	2007	17568575	\N	\N	\N	2	f	\N
113988	\N	Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients.	{"Li D","Lu W","Zhu J-Y","Gao J","Lou Y-Q","Zhang G-L"}	Journal of clinical pharmacy and therapeutics	10	\N	\N	2007	17875118	\N	\N	\N	2	f	\N
113990	\N	Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients.	{"Cheung Chi Yuen","Op den Buijsch Robert A M","Wong Kim Ming","Chan Hoi Wong","Chau Ka Foon","Li Chun Sang","Leung Kay Tai","Kwan Tze Hoi","de Vrie Johan E","Wijnen Petal Ahm","van Dieijen-Visser Marja P","Bekers Otto"}	Pharmacogenomics	6	\N	\N	2006	16753004	\N	\N	\N	2	f	\N
113994	\N	Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.	{"Zhang Xin","Liu Zhi-hong","Zheng Jing-min","Chen Zhao-hong","Tang Zheng","Chen Jin-song","Li Lei-shi"}	Clinical transplantation	10	\N	\N	2005	16146556	\N	\N	\N	2	f	\N
113996	\N	Novel single nucleotide polymorphisms in interleukin 6 affect tacrolimus metabolism in liver transplant patients.	{"Chen Dawei","Fan Junwei","Guo Feng","Qin Shengying","Wang Zhaowen","Peng Zhihai"}	PloS one	0	\N	\N	2013	23991193	\N	\N	\N	2	f	\N
114000	\N	Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation.	{"Yu Songfeng","Wu Lihua","Jin Jing","Yan Sheng","Jiang Guoping","Xie Haiyang","Zheng Shusen"}	Transplantation	1	\N	\N	2006	16421475	\N	\N	\N	2	f	\N
114002	\N	Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients.	{"Chen Dawei","Guo Feng","Shi Jinxiu","Zhang Chenhui","Wang Zhaowen","Fan Junwei","Peng Zhihai"}	Drug metabolism and pharmacokinetics	0	\N	\N	2014	24351870	\N	\N	\N	2	f	\N
114004	\N	Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.	{"Shih Pei-Shan","Huang Jin-Ding"}	Drug metabolism and disposition: the biological fate of chemicals	12	\N	\N	2002	12433824	\N	\N	\N	2	f	\N
114011	\N	Genetic polymorphisms of pharmacogenomic VIP variants in the Kyrgyz population from northwest China.	{"Yunus Zulfiya","Liu Lijun","Wang Hong","Zhang Le","Li Xiaolan","Geng Tingting","Kang Longli","Jin Tianbo","Chen Chao"}	Gene	10	\N	\N	2013	23954225	\N	\N	\N	2	f	\N
114015	\N	Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients.	{"Xing Jiazhen","Zhang Xiaoqing","Fan Junwei","Shen Bin","Men Tongyi","Wang Jianning"}	European journal of clinical pharmacology	2	\N	\N	2015	25487141	\N	\N	\N	2	f	\N
114017	\N	Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation.	{"Wang Zhaowen","Wu Shaohan","Chen Dawei","Guo Feng","Zhong Lin","Fan Junwei","Peng Zhihai"}	European journal of clinical pharmacology	8	\N	\N	2014	24820765	\N	\N	\N	2	f	\N
114019	\N	Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population.	{"Saeki Mayumi","Saito Yoshiro","Nakamura Takahiro","Murayama Norie","Kim Su-Ryang","Ozawa Shogo","Komamura Kazuo","Ueno Kazuyuki","Kamakura Shiro","Nakajima Toshiharu","Saito Hirohisa","Kitamura Yutaka","Kamatani Naoyuki","Sawada Jun-ichi"}	Human mutation	6	\N	\N	2003	14961555	\N	\N	\N	2	f	\N
114025	\N	Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients.	{"Niioka Takenori","Kagaya Hideaki","Miura Masatomo","Numakura Kazuyuki","Saito Mitsuru","Inoue Takamitsu","Habuchi Tomonori","Satoh Shigeru"}	European journal of clinical pharmacology	9	\N	\N	2013	23733010	\N	\N	\N	2	f	\N
114027	\N	Impact of CYP3A5 genetic polymorphism on cross-reactivity in tacrolimus chemiluminescent immunoassay in kidney transplant recipients.	{"Hirano Kumi","Naito Takafumi","Mino Yasuaki","Takayama Tatsuya","Ozono Seiichiro","Kawakami Junichi"}	Clinica chimica acta; international journal of clinical chemistry	12	\N	\N	2012	22889968	\N	\N	\N	2	f	\N
114029	\N	Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.	{"Niioka Takenori","Satoh Shigeru","Kagaya Hideaki","Numakura Kazuyuki","Inoue Takamitsu","Saito Mitsuru","Narita Shintaro","Tsuchiya Norihiko","Habuchi Tomonori","Miura Masatomo"}	Transplantation	11	\N	\N	2012	23073468	\N	\N	\N	2	f	\N
114033	\N	Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients.	{"Muraki Yuichi","Usui Masanobu","Isaji Shuji","Mizuno Shugo","Nakatani Kaname","Yamada Tomomi","Iwamoto Takuya","Uemoto Shinji","Nobori Tsutomu","Okuda Masahiro"}	Annals of transplantation	0	\N	\N	2011	22210422	\N	\N	\N	2	f	\N
114035	\N	CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients.	{"Satoh Shigeru","Saito Mitsuru","Inoue Takamitsu","Kagaya Hideaki","Miura Masatomo","Inoue Kazuyuki","Komatsuda Atsushi","Tsuchiya Norihiko","Suzuki Toshio","Habuchi Tomonori"}	European journal of clinical pharmacology	5	\N	\N	2009	19125240	\N	\N	\N	2	f	\N
114037	\N	Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients.	{"Satoh Shigeru","Kagaya Hideaki","Saito Mitsuru","Inoue Takamitsu","Miura Masatomo","Inoue Kazuyuki","Numakura Kazuyuki","Tsuchiya Norihiko","Tada Hitoshi","Suzuki Toshio","Habuchi Tomonori"}	British journal of clinical pharmacology	8	\N	\N	2008	18429967	\N	\N	\N	2	f	\N
114041	\N	Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus.	{"Hirai Fumihito","Takatsu Noritaka","Yano Yutaka","Satou Yuhou","Takahashi Haruhiko","Ishikawa Satoshi","Tsurumi Kozue","Hisabe Takashi","Matsui Toshiyuki"}	Journal of gastroenterology and hepatology	1	\N	\N	2014	24033383	\N	\N	\N	2	f	\N
114043	\N	Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation.	{"Yanagimachi Masakatsu","Naruto Takuya","Tanoshima Reo","Kato Hiromi","Yokosuka Tomoko","Kajiwara Ryosuke","Fujii Hisaki","Tanaka Fumiko","Goto Hiroaki","Yagihashi Tatsuhiko","Kosaki Kenjiro","Yokota Shumpei"}	Clinical transplantation	0	\N	\N	2010	20030680	\N	\N	\N	2	f	\N
114047	\N	Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.	{"Tada H","Tsuchiya N","Satoh S","Kagaya H","Li Z","Sato K","Miura M","Suzuki T","Kato T","Habuchi T"}	Transplantation proceedings	5	\N	\N	2005	15919447	\N	\N	\N	2	f	\N
114049	\N	Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.	{"Tsuchiya Norihiko","Satoh Shigeru","Tada Hitoshi","Li Zhenhua","Ohyama Chikara","Sato Kazunari","Suzuki Toshio","Habuchi Tomonori","Kato Tetsuro"}	Transplantation	10	\N	\N	2004	15502717	\N	\N	\N	2	f	\N
114051	\N	CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.	{"Goto Maki","Masuda Satohiro","Kiuchi Tetsuya","Ogura Yasuhiro","Oike Fumitaka","Okuda Masahiro","Tanaka Koichi","Inui Ken-ichi"}	Pharmacogenetics	7	\N	\N	2004	15226679	\N	\N	\N	2	f	\N
114055	\N	Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation.	{"Niioka Takenori","Kagaya Hideaki","Saito Mitsuru","Inoue Takamitsu","Numakura Kazuyuki","Habuchi Tomonori","Satoh Shigeru","Miura Masatomo"}	International journal of molecular sciences	1	\N	\N	2015	25594874	\N	\N	\N	2	f	\N
114059	\N	Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.	{"Yoo Hee-Doo","Cho Hea-Young","Lee Yong-Bok"}	British journal of clinical pharmacology	1	\N	\N	2010	20078610	\N	\N	\N	2	f	\N
114065	\N	Identification of factors affecting tacrolimus level and 5-year clinical outcome in kidney transplant patients.	{"Kim In-Wha","Noh Hyejin","Ji Eunhee","Han Nayoung","Hong Su Hyun","Ha Jongwon","Burckart Gilbert J","Oh Jung Mi"}	Basic & clinical pharmacology & toxicology	10	\N	\N	2012	22469198	\N	\N	\N	2	f	\N
114067	\N	Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.	{"Ji Eunhee","Choi Leena","Suh Kyung-Suk","Cho Joo-Youn","Han Nayoung","Oh Jung Mi"}	Transplantation	10	\N	\N	2012	22992768	\N	\N	\N	2	f	\N
114071	\N	Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.	{"Kim In-Wha","Moon Yoo Jin","Ji Eunhee","Kim Kyung Im","Han Nayoung","Kim Sung Ju","Shin Wan Gyoon","Ha Jongwon","Yoon Jeong-Hyun","Lee Hye Suk","Oh Jung Mi"}	European journal of clinical pharmacology	5	\N	\N	2012	22183771	\N	\N	\N	2	f	\N
114073	\N	Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.	{"Han Nayoung","Yun Hwi-yeol","Hong Jin-yi","Kim In-Wha","Ji Eunhee","Hong Su Hyun","Kim Yon Su","Ha Jongwon","Shin Wan Gyoon","Oh Jung Mi"}	European journal of clinical pharmacology	1	\N	\N	2013	22660440	\N	\N	\N	2	f	\N
114075	\N	CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients.	{"Min Sang-Il","Kim Seong Yup","Ahn Sang Hyun","Min Seung-Kee","Kim Si Hwa","Kim Yon Su","Moon Kyung Chul","Oh Jung Mi","Kim Sang Joon","Ha Jongwon"}	Transplantation	12	\N	\N	2010	21076384	\N	\N	\N	2	f	\N
114079	\N	Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.	{"Jun Kyung Ran","Lee Woochang","Jang Mi Sook","Chun Sail","Song Gi-Won","Park Kwan Tae","Lee Sung Gyu","Han Duck Jong","Kang Changwon","Cho Dae-Yeon","Kim Jin Q","Min Won-Ki"}	Transplantation	4	\N	\N	2009	19384171	\N	\N	\N	2	f	\N
114081	\N	Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.	{"Choi Ji H","Lee Yoon J","Jang Seong B","Lee Jong-Eun","Kim Kyung H","Park Kyungsoo"}	British journal of clinical pharmacology	8	\N	\N	2007	17391324	\N	\N	\N	2	f	\N
114085	\N	Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.	{"Cho J-H","Yoon Y-D","Park J-Y","Song E-J","Choi J-Y","Yoon S-H","Park S-H","Kim Y-L","Kim C-D"}	Transplantation proceedings	1	\N	\N	2012	22310591	\N	\N	\N	2	f	\N
114088	\N	Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5.	{"Wu M-J","Chang C-H","Cheng C-Y","Shu K-H","Chen C-H","Cheng C-H","Yu T-M","Chuang Y-W","Huang S-T","Tsai S-F","Ho H-C","Li J-R","Shiu Y-N","Fu Y-C"}	Transplantation proceedings	0	\N	\N	2014	24655974	\N	\N	\N	2	f	\N
114090	\N	Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.	{"Vannaprasaht Suda","Reungjui Sirirat","Supanya Darika","Sirivongs Dhavee","Pongskul Cholatip","Avihingsanon Yingyos","Tassaneeyakul Wichittra"}	Clinical therapeutics	11	\N	\N	2013	24120259	\N	\N	\N	2	f	\N
114103	\N	In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.	{"de Jonge H","de Loor H","Verbeke K","Vanrenterghem Y","Kuypers D R"}	Clinical pharmacology and therapeutics	9	\N	\N	2012	22871995	\N	\N	\N	2	f	\N
114105	\N	The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.	{"Haufroid Vincent","Mourad Michel","Van Kerckhove Valérie","Wawrzyniak Jeremie","De Meyer Martine","Eddour Djamila Chaib","Malaise Jacques","Lison Dominique","Squifflet Jean-Paul","Wallemacq Pierre"}	Pharmacogenetics	3	\N	\N	2004	15167702	\N	\N	\N	2	f	\N
114107	\N	Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina.	{"Semiz Sabina","Dujić Tanja","Ostanek Barbara","Prnjavorac Besim","Bego Tamer","Malenica Maja","Mlinar Barbara","Marc Janja","Causević Adlija"}	Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina	2	\N	\N	2011	21263403	\N	\N	\N	2	f	\N
114112	\N	CYP3A5 genetic polymorphisms in different ethnic populations.	{"Roy Jean-Nicholas","Lajoie Julie","Zijenah Lynn S","Barama Azemi","Poirier Charles","Ward Brian J","Roger Michel"}	Drug metabolism and disposition: the biological fate of chemicals	7	\N	\N	2005	15833928	\N	\N	\N	2	f	\N
114116	\N	Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.	{"Hesselink Dennis A","van Schaik Ron H N","van der Heiden Ilse P","van der Werf Marloes","Gregoor Peter J H Smak","Lindemans Jan","Weimar Willem","van Gelder Teun"}	Clinical pharmacology and therapeutics	9	\N	\N	2003	12966368	\N	\N	\N	2	f	\N
114122	\N	Ethnic differences in the distribution of CYP3A5 gene polymorphisms.	{"Quaranta S","Chevalier D","Allorge D","Lo-Guidice J M","Migot-Nabias F","Kenani A","Imbenotte M","Broly F","Lacarelle B","Lhermitte M"}	Xenobiotica; the fate of foreign compounds in biological systems	12	\N	\N	2006	17162466	\N	\N	\N	2	f	\N
114124	\N	Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.	{"Zhao W","Elie V","Roussey G","Brochard K","Niaudet P","Leroy V","Loirat C","Cochat P","Cloarec S","André J L","Garaix F","Bensman A","Fakhoury M","Jacqz-Aigrain E"}	Clinical pharmacology and therapeutics	12	\N	\N	2009	19865079	\N	\N	\N	2	f	\N
114126	\N	Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations.	{"Wehland Markus","Bauer Steffen","Brakemeier Susanne","Burgwinkel Philip","Glander Petra","Kreutz Reinhold","Lorkowski Christine","Slowinski Torsten","Neumayer Hans H","Budde Klemens"}	Pharmacogenetics and genomics	4	\N	\N	2011	20818295	\N	\N	\N	2	f	\N
114130	\N	CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients.	{"Renders L","Frisman M","Ufer M","Mosyagin I","Haenisch S","Ott U","Caliebe A","Dechant M","Braun F","Kunzendorf U","Cascorbi I"}	Clinical pharmacology and therapeutics	2	\N	\N	2007	17192769	\N	\N	\N	2	f	\N
114134	\N	Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.	{"Provenzani Alessio","Notarbartolo Monica","Labbozzetta Manuela","Poma Paola","Vizzini Giovanni","Salis Paola","Caccamo Chiara","Bertani Tullio","Palazzo Ugo","Polidori Piera","Gridelli Bruno","D'Alessandro Natale"}	International journal of molecular medicine	12	\N	\N	2011	21922127	\N	\N	\N	2	f	\N
114136	\N	The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation.	{"Stratta P","Quaglia M","Cena T","Antoniotti R","Fenoglio R","Menegotto A","Ferrante D","Genazzani A","Terrazzino S","Magnani C"}	European journal of clinical pharmacology	5	\N	\N	2012	22101623	\N	\N	\N	2	f	\N
114140	\N	The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients.	{"Provenzani Alessio","Notarbartolo Monica","Labbozzetta Manuela","Poma Paola","Biondi Filippo","Sanguedolce Rosario","Vizzini Giovanni","Palazzo Ugo","Polidori Piera","Triolo Fabio","Gridelli Bruno","D'Alessandro Natale"}	Annals of transplantation	0	\N	\N	2009	19289993	\N	\N	\N	2	f	\N
114142	\N	Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors.	{"Ferraresso Mariano","Turolo Stefano","Ghio Luciana","Tirelli Amedea S","Belingheri Mirco","Villa Roberta","Groppali Elena","Edefonti Alberto"}	Clinical and experimental hypertension (New York, N.Y. : 1993)	0	\N	\N	2011	21851254	\N	\N	\N	2	f	\N
114144	\N	The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.	{"Tirelli Silvia","Ferraresso Mariano","Ghio Luciana","Meregalli Elisa","Martina Valentina","Belingheri Mirco","Mattiello Camilla","Torresani Emilio","Edefonti Alberto"}	Medical science monitor : international medical journal of experimental and clinical research	5	\N	\N	2008	18443548	\N	\N	\N	2	f	\N
114150	\N	CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.	{"Kurzawski Mateusz","Dąbrowska Justyna","Dziewanowski Krzysztof","Domański Leszek","Perużyńska Magdalena","Droździk Marek"}	Pharmacogenomics	2	\N	\N	2014	24444408	\N	\N	\N	2	f	\N
114155	\N	CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans.	{"Sinues Blanca","Vicente Jorge","Fanlo Ana","Vasquez Patricia","Medina Juan Carlos","Mayayo Esteban","Conde Blanca","Arenaz Izaskun","Martinez-Jarreta Begoña"}	Therapeutic drug monitoring	8	\N	\N	2007	17667794	\N	\N	\N	2	f	\N
114157	\N	Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.	{"Gervasini Guillermo","Vizcaino Sonia","Gasiba Carolina","Carrillo Juan Antonio","Benitez Julio"}	Therapeutic drug monitoring	12	\N	\N	2005	16306861	\N	\N	\N	2	f	\N
114159	\N	Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients.	{"Gómez-Bravo Miguel Angel","Salcedo Magdalena","Fondevila Constantino","Suarez Francisco","Castellote José","Rufian Sebastián","Pons José Antonio","Alamo José María","Millán Olga","Brunet Mercè"}	Journal of clinical pharmacology	11	\N	\N	2013	23900887	\N	\N	\N	2	f	\N
114163	\N	Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285.	{"Bosó Virginia","Herrero María José","Bea Sergio","Galiana María","Marrero Patricia","Marqués María Remedios","Hernández Julio","Sánchez-Plumed Jaime","Poveda José Luis","Aliño Salvador F"}	Drug metabolism and disposition: the biological fate of chemicals	2	\N	\N	2013	23175667	\N	\N	\N	2	f	\N
114167	\N	Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.	{"Gervasini Guillermo","Garcia Montserrat","Macias Rosa María","Cubero Juan Jose","Caravaca Francisco","Benitez Julio"}	Transplant international : official journal of the European Society for Organ Transplantation	4	\N	\N	2012	22369694	\N	\N	\N	2	f	\N
114169	\N	Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes.	{"Tavira Beatriz","Coto Eliecer","Garciá Eliecer Coto","Díaz-Corte Carmen","Ortega Francisco","Arias Manuel","Torres Armando","Díaz Juan M","Selgas Rafael","López-Larrea Carlos","Campistol Josep M","Alvarez Victoria","Alvarezca Victoria","REDINREN Pharmacogenetics group"}	Clinical chemistry and laboratory medicine	5	\N	\N	2011	21480817	\N	\N	\N	2	f	\N
114171	\N	Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.	{"Barrera-Pulido L","Aguilera-García I","Docobo-Pérez F","Alamo-Martínez J M","Pareja-Ciuró F","Nuñez-Roldán A","Gómez-Bravo M A","Bernardos-Rodríguez A"}	Transplantation proceedings	11	\N	\N	2008	19010156	\N	\N	\N	2	f	\N
114173	\N	CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.	{"Mirghani Rajaa A","Sayi Jane","Aklillu Eleni","Allqvist Annika","Jande Mary","Wennerholm Agneta","Eriksen Jaran","Herben Virginie M M","Jones Barry C","Gustafsson Lars L","Bertilsson Leif"}	Pharmacogenetics and genomics	9	\N	\N	2006	16906018	\N	\N	\N	2	f	\N
114177	\N	Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.	{"Cusinato Diego Alberto C","Lacchini Riccardo","Romao Elen A","Moysés-Neto Miguel","Coelho Eduardo B"}	British journal of clinical pharmacology	8	\N	\N	2014	24528196	\N	\N	\N	2	f	\N
114179	\N	Global pharmacogenomics: distribution of CYP3A5 polymorphisms and phenotypes in the Brazilian population.	{"Suarez-Kurtz Guilherme","Vargens Daniela D","Santoro Ana Beatriz","Hutz Mara H","de Moraes Maria Elisabete","Pena Sérgio D J","Ribeiro-dos-Santos Ândrea","Romano-Silva Marco A","Struchiner Claudio José"}	PloS one	0	\N	\N	2014	24427273	\N	\N	\N	2	f	\N
114185	\N	CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing.	{"García-Roca Pilar","Medeiros Mara","Reyes Herlinda","Rodríguez-Espino Benjamín Antonio","Alberú Josefina","Ortiz Lourdes","Vásquez-Perdomo Mayela","Elizondo Guillermo","Morales-Buenrostro Luis Eduardo","Mancilla Urrea Eduardo","Castañeda-Hernández Gilberto"}	Archives of medical research	5	\N	\N	2012	22704849	\N	\N	\N	2	f	\N
114193	\N	Frequencies of CYP3A5*1/*3 variants in a Moroccan population and effect on tacrolimus daily dose requirements in renal transplant patients.	{"Elmachad Mustapha","Elkabbaj Driss","Elkerch Fatiha","Laarabi Fatima Zahra","Barkat Amina","Oualim Zouhir","Sefiani Abdelaziz"}	Genetic testing and molecular biomarkers	6	\N	\N	2012	22304537	\N	\N	\N	2	f	\N
114202	\N	Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.	{"Rahsaz Marjan","Azarpira Negar","Nikeghbalian Saman","Aghdaie Mahdokht H","Geramizadeh Bita","Moini Maryam","Banihashemi Mehrzad","Darai Masumeh","Malekpour Zahra","Malekhosseini Seid Ali"}	Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation	2	\N	\N	2012	22309416	\N	\N	\N	2	f	\N
114208	\N	A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.	{"Sy Sherwin K B","Heuberger Jules","Shilbayeh Sireen","Conrado Daniela J","Derendorf Hartmut"}	The AAPS journal	10	\N	\N	2013	23990505	\N	\N	\N	2	f	\N
114210	\N	The impact of CYP3A5 and MDR1 polymorphisms on tacrolimus dosage requirements and trough concentrations in pediatric renal transplant recipients.	{"Shilbayeh Sireen","Zmeili Rawan","Almardini Reham Issa"}	Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia	11	\N	\N	2013	24231473	\N	\N	\N	2	f	\N
114227	\N	Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.	{"Gebeyehu E","Engidawork E","Bijnsdorp A","Aminy A","Diczfalusy U","Aklillu E"}	The pharmacogenomics journal	4	\N	\N	2011	20231858	\N	\N	\N	2	f	\N
114253	\N	Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?	{"Kudzi William","Dodoo Alexander N O","Mills Jeremy J"}	BMC medical genetics	7	\N	\N	2010	20630055	\N	\N	\N	2	f	\N
113839	\N	Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients.	{"Singh Onkar","Sandanaraj Edwin","Subramanian Koilan","Lee Lai Heng","Chowbay Balram"}	Drug metabolism and pharmacokinetics	0	\N	\N	2011	21084764	\N	\N	\N	2	f	\N
113843	\N	Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.	{"Bress Adam","Patel Shitalben R","Perera Minoli A","Campbell Richard T","Kittles Rick A","Cavallari Larisa H"}	Pharmacogenomics	12	\N	\N	2012	23215885	\N	\N	\N	2	f	\N
113895	\N	CYP4F2 genetic variant alters required warfarin dose.	{"Caldwell Michael D","Awad Tarif","Johnson Julie A","Gage Brian F","Falkowski Mat","Gardina Paul","Hubbard Jason","Turpaz Yaron","Langaee Taimour Y","Eby Charles","King Cristi R","Brower Amy","Schmelzer John R","Glurich Ingrid","Vidaillet Humberto J","Yale Steven H","Qi Zhang Kai","Berg Richard L","Burmester James K"}	Blood	4	\N	\N	2008	18250228	\N	\N	\N	2	f	\N
113899	\N	Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study.	{"Bejarano-Achache Idit","Levy Liran","Mlynarsky Liat","Bialer Meir","Muszkat Mordechai","Caraco Yoseph"}	Clinical therapeutics	4	\N	\N	2012	22417713	\N	\N	\N	2	f	\N
113914	\N	Genome at juncture of early human migration: a systematic analysis of two whole genomes and thirteen exomes from Kuwaiti population subgroup of inferred Saudi Arabian tribe ancestry.	{"Alsmadi Osama","John Sumi E","Thareja Gaurav","Hebbar Prashantha","Antony Dinu","Behbehani Kazem","Thanaraj Thangavel Alphonse"}	PloS one	0	\N	\N	2014	24896259	\N	\N	\N	2	f	\N
117252	\N	Analysis of protein-coding genetic variation in 60,706 humans.	{"Lek Monkol","Karczewski Konrad J","Minikel Eric V","Samocha Kaitlin E","Banks Eric","Fennell Timothy","O'Donnell-Luria Anne H","Ware James S","Hill Andrew J","Cummings Beryl B","Tukiainen Taru","Birnbaum Daniel P","Kosmicki Jack A","Duncan Laramie E","Estrada Karol","Zhao Fengmei","Zou James","Pierce-Hoffman Emma","Berghout Joanne","Cooper David N","Deflaux Nicole","DePristo Mark","Do Ron","Flannick Jason","Fromer Menachem","Gauthier Laura","Goldstein Jackie","Gupta Namrata","Howrigan Daniel","Kiezun Adam","Kurki Mitja I","Moonshine Ami Levy","Natarajan Pradeep","Orozco Lorena","Peloso Gina M","Poplin Ryan","Rivas Manuel A","Ruano-Rubio Valentin","Rose Samuel A","Ruderfer Douglas M","Shakir Khalid","Stenson Peter D","Stevens Christine","Thomas Brett P","Tiao Grace","Tusie-Luna Maria T","Weisburd Ben","Won Hong-Hee","Yu Dongmei","Altshuler David M","Ardissino Diego","Boehnke Michael","Danesh John","Donnelly Stacey","Elosua Roberto","Florez Jose C","Gabriel Stacey B","Getz Gad","Glatt Stephen J","Hultman Christina M","Kathiresan Sekar","Laakso Markku","McCarroll Steven","McCarthy Mark I","McGovern Dermot","McPherson Ruth","Neale Benjamin M","Palotie Aarno","Purcell Shaun M","Saleheen Danish","Scharf Jeremiah M","Sklar Pamela","Sullivan Patrick F","Tuomilehto Jaakko","Tsuang Ming T","Watkins Hugh C","Wilson James G","Daly Mark J","MacArthur Daniel G","Exome Aggregation Consortium"}	Nature	8	\N	\N	2016	27535533	\N	\N	\N	2	f	\N
113528	\N	Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations.	{"González-Galarza Faviel F","Takeshita Louise Y C","Santos Eduardo J M","Kempson Felicity","Maia Maria Helena Thomaz","da Silva Andrea Luciana Soares","Teles e Silva André Luiz","Ghattaoraya Gurpreet S","Alfirevic Ana","Jones Andrew R","Middleton Derek"}	Nucleic acids research	1	\N	\N	2015	25414323	\N	\N	\N	2	f	\N
113539	\N	High-resolution HLA allele and haplotype frequencies in majority and minority populations of Costa Rica and Nicaragua: Differential admixture proportions in neighboring countries.	{"Arrieta-Bolaños E","Madrigal-Sánchez J J","Stein J E","Órlich-Pérez P","Moreira-Espinoza M J","Paredes-Carias E","Vanegas-Padilla Y","Salazar-Sánchez L","Madrigal J A","Marsh S G E","Shaw B E"}	HLA	6	\N	\N	2018	29687625	\N	\N	\N	2	f	\N
113559	\N	Study of Colombia North Wiwa El Encanto Amerindians HLA- genes: Pacific Islanders relatedness.	{"Arnaiz-Villena Antonio","Palacio-Grüber Jose","Juarez Ignacio","Muñiz Ester","Hernández Ennio","Bayona Brayan","Campos Cristina","Nuñez Jorge","Lopez-Nares Adrian","Martin-Villa Manuel","Silvera Carlos"}	Human immunology	7	\N	\N	2018	29729321	\N	\N	\N	2	f	\N
113563	\N	HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis.	{"Khor Amy Hui-Ping","Lim Kheng-Seang","Tan Chong-Tin","Wong Su-Ming","Ng Ching-Ching"}	Epilepsia	11	\N	\N	2014	25266342	\N	\N	\N	2	f	\N
113574	\N	Human leucocyte antigen (HLA)-A, -B, -C, -DRB1 and -DQB1 haplotype frequencies from 2491 cord blood units from Tamil speaking population from Tamil Nadu, India.	{"Narayan Saranya","Maiers Martin","Halagan Mike","Sathishkannan Arunadevi","Naganathan Chandramouleeswaran","Madbouly Abeer","Periathiruvadi Srinivasan"}	Molecular biology reports	12	\N	\N	2018	30229475	\N	\N	\N	2	f	\N
113576	\N	HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs.	{"Park Hye Jung","Kim Young Joo","Kim Dong Hyun","Kim Junho","Park Kyung Hee","Park Jung Won","Lee Jae Hyun"}	Yonsei medical journal	1	\N	\N	2016	26632391	\N	\N	\N	2	f	\N
113578	\N	HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity.	{"Puangpetch Apichaya","Koomdee Napatrupron","Chamnanphol Montri","Jantararoungtong Thawinee","Santon Siwalee","Prommas Santirhat","Hongkaew Yaowaluck","Sukasem Chonlaphat"}	Frontiers in genetics	0	\N	\N	2014	25657656	\N	\N	\N	2	f	\N
113580	\N	HLA-A, HLA-B and HLA-DRB1 allele and haplotype frequencies of 10 918 Koreans from bone marrow donor registry in Korea.	{"Park H","Lee Y-J","Song E Y","Park M H"}	International journal of immunogenetics	10	\N	\N	2016	27511726	\N	\N	\N	2	f	\N
113582	\N	HLA-A, -B and -DRB1 allele and haplotype frequencies of 8333 Chinese Han from the Zhejiang province, China.	{"He Y","Zhang W","Chen N","Wang W","He J","Han Z","Tao S","Dong L","Zhu F","Lv H"}	International journal of immunogenetics	4	\N	\N	2016	26919533	\N	\N	\N	2	f	\N
115400	\N	Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study.	{"Ikeda N","Kojima H","Nishikawa M","Hayashi K","Futagami T","Tsujino T","Kusunoki Y","Fujii N","Suegami S","Miyazaki Y","Middleton D","Tanaka H","Saji H"}	Tissue antigens	4	\N	\N	2015	25789826	\N	\N	\N	2	f	\N
113584	\N	The Adaptive Change of HLA-DRB1 Allele Frequencies Caused by Natural Selection in a Mongolian Population That Migrated to the South of China.	{"Sun Hao","Yang Zhaoqing","Lin Keqin","Liu Shuyuan","Huang Kai","Wang Xiuyun","Chu Jiayou","Huang Xiaoqin"}	PloS one	0	\N	\N	2015	26230582	\N	\N	\N	2	f	\N
113656	\N	Distribution of HLA-A, -B, and -C alleles and HLA/KIR combinations in Han population in China.	{"Shen Yunsong","Cao Danfeng","Li Yalin","Kulski J K","Shi Lei","Jiang Hongjun","Ma Qianli","Yu Jiankun","Zhou Jingxian","Yao Yufeng","Shi Li"}	Journal of immunology research	0	\N	\N	2014	24995346	\N	\N	\N	2	f	\N
113660	\N	HLA alleles and haplotypes in Burmese (Myanmarese) and Karen in Thailand.	{"Kongmaroeng C","Romphruk A","Puapairoj C","Leelayuwat C","Kulski J K","Inoko H","Dunn D S","Romphruk A V"}	Tissue antigens	9	\N	\N	2015	26265055	\N	\N	\N	2	f	\N
113665	\N	Allelic and haplotype diversity of HLA-A, HLA-B and HLA-DRB1 gene at high resolution in the Nanning Han population.	{"Pei YongFeng","Huang HuiNi","Li HengCong","Chen JieRun","Wu GuoGuang"}	International journal of immunogenetics	8	\N	\N	2018	29908012	\N	\N	\N	2	f	\N
113667	\N	HLA Pharmacogenetic Markers of Drug Hypersensitivity in a Thai Population.	{"Nakkam Nontaya","Konyoung Parinya","Kanjanawart Sirimas","Saksit Niwat","Kongpan Thachanan","Khaeso Kanyarat","Khunarkornsiri Usanee","Dornsena Areerat","Tassaneeyakul Wongwiwat","Tassaneeyakul Wichittra"}	Frontiers in genetics	0	\N	\N	2018	30127801	\N	\N	\N	2	f	\N
113669	\N	Full-length next-generation sequencing of HLA class I and II genes in a cohort from Thailand.	{"Geretz Aviva","Ehrenberg Philip K","Bouckenooghe Alain","Fernández Viña Marcelo A","Michael Nelson L","Chansinghakule Danaya","Limkittikul Kriengsak","Thomas Rasmi"}	Human immunology	11	\N	\N	2018	30243890	\N	\N	\N	2	f	\N
113673	\N	Prevalence of HLA-DQA1 alleles and haplotypes in blood donors resident in Wales.	{"Lemin A J","Darke C"}	International journal of immunogenetics	12	\N	\N	2014	25345618	\N	\N	\N	2	f	\N
113753	\N	HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in the Serbian population.	{"Andric Zorana","Popadic Dusan","Jovanovic Barbara","Jaglicic Ivana","Bojic Svetlana","Simonovic Ruzica"}	Human immunology	3	\N	\N	2014	24374041	\N	\N	\N	2	f	\N
113757	\N	High-resolution HLA-A, HLA-B, and HLA-DRB1 haplotype frequencies from the French Bone Marrow Donor Registry.	{"Gourraud Pierre-Antoine","Pappas Derek James","Baouz Amar","Balère Marie-Lorraine","Garnier Federico","Marry Evelyne"}	Human immunology	5	\N	\N	2015	25637665	\N	\N	\N	2	f	\N
113774	\N	Population variation of HLA genes in rural communities in Brazil, the Quilombos from the Vale do Ribeira, São Paulo - Brazil.	{"Nunes Kelly","Piovezan Bruno","Torres Margareth A","Pontes Gerlndia N","Kimura Lilian","Carnavalli Juliana E P","Mingroni Netto Regina Célia","Moraes Maria Elisa","Meyer Diogo"}	Human immunology	6	\N	\N	2016	27060779	\N	\N	\N	2	f	\N
115614	\N	Frequency of HLA-A alleles in the Syrian population genotyped by sequence-based typing.	{"Madania A","Ghoury I","Al-Ashkar W","Nweder S","Zarzour H"}	International journal of immunogenetics	10	\N	\N	2014	25053398	\N	\N	\N	2	f	\N
113814	\N	Human Leukocyte Antigen (HLA) Class I and II Polymorphism in Iranian Healthy Population from Yazd Province.	{"Nikbin Behrouz","Nicknam Mohammad Hossein","Hadinedoushan Hossein","Ansaripour Bita","Moradi Batol","Yekaninejad Mirsaeed","Aminikhah Mahdi","Ranjbar Mohammad Mehdi","Amirzargar Aliakbar"}	Iranian journal of allergy, asthma, and immunology	2	\N	\N	2017	28417619	\N	\N	\N	2	f	\N
113759	\N	HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in a population of 432 healthy unrelated individuals from Albania.	{"Sulcebe Genc","Shyti Erkena"}	Human immunology	8	\N	\N	2016	27262454	\N	\N	\N	2	f	\N
117595	\N	Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler&reg;-based method.	{"Aklillu Eleni","Mugusi Sabina","Ngaimisi Eliford","Hoffmann Michael Marcus","König Sonja","Ziesenitz Victoria","Mikus Gerd","Haefeli Walter Emil","Weiss Johanna"}	European journal of clinical pharmacology	11	\N	\N	2011	21630030	\N	\N	\N	2	f	\N
115325	\N	NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity.	{"Moriyama Takaya","Nishii Rina","Perez-Andreu Virginia","Yang Wenjian","Klussmann Federico Antillon","Zhao Xujie","Lin Ting-Nien","Hoshitsuki Keito","Nersting Jacob","Kihira Kentaro","Hofmann Ute","Komada Yoshihiro","Kato Motohiro","McCorkle Robert","Li Lie","Koh Katsuyoshi","Najera Cesar Rolando","Kham Shirley Kow-Yin","Isobe Tomoya","Chen Zhiwei","Chiew Edwynn Kean-Hui","Bhojwani Deepa","Jeffries Cynthia","Lu Yan","Schwab Matthias","Inaba Hiroto","Pui Ching-Hon","Relling Mary V","Manabe Atsushi","Hori Hiroki","Schmiegelow Kjeld","Yeoh Allen E J","Evans William E","Yang Jun J"}	Nature genetics	4	\N	\N	2016	26878724	\N	\N	\N	2	f	\N
115335	\N	NUDT15 p.R139C variant is common and strongly associated with azathioprine-induced early leukopenia and severe alopecia in Korean patients with various neurological diseases.	{"Kim Sun-Young","Shin Jin-Hong","Park Jin-Sung","Kang Sa-Yoon","Nam Tai-Seung","Kim Jong Kuk","Park Ki-Jong","Huh So-Young","Oh Ji Seon","Kang Boram","Kim Dae-Seong"}	Journal of the neurological sciences	7	\N	\N	2017	28566182	\N	\N	\N	2	f	\N
117539	\N	Global analysis of genetic variation in SLCO1B1.	{"Pasanen Marja K","Neuvonen Pertti J","Niemi Mikko"}	Pharmacogenomics	1	\N	\N	2008	18154446	\N	\N	\N	2	f	\N
117541	\N	Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.	{"Lee Edmund","Ryan Stephen","Birmingham Bruce","Zalikowski Julie","March Ruth","Ambrose Helen","Moore Rachael","Lee Caroline","Chen Yusong","Schneck Dennis"}	Clinical pharmacology and therapeutics	10	\N	\N	2005	16198652	\N	\N	\N	2	f	\N
117543	\N	Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.	{"Xiang Xiaoqiang","Jada Srinivasa Rao","Li Hui Hua","Fan Lu","Tham Lai San","Wong Chiung Ing","Lee Soo Chin","Lim Robert","Zhou Qing Yu","Goh Boon Cher","Tan Eng Huat","Chowbay Balram"}	Pharmacogenetics and genomics	9	\N	\N	2006	16906022	\N	\N	\N	2	f	\N
117548	\N	Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis.	{"Nozawa Takashi","Nakajima Miki","Tamai Ikumi","Noda Kumiko","Nezu Jun-Ichi","Sai Yoshimichi","Tsuji Akira","Yokoi Tsuyoshi"}	The Journal of pharmacology and experimental therapeutics	8	\N	\N	2002	12130747	\N	\N	\N	2	f	\N
117550	\N	Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.	{"Nishizato Yohei","Ieiri Ichiro","Suzuki Hiroshi","Kimura Miyuki","Kawabata Kiyoshi","Hirota Takeshi","Takane Hiroshi","Irie Shin","Kusuhara Hiroyuki","Urasaki Yoko","Urae Akinori","Higuchi Shun","Otsubo Kenji","Sugiyama Yuichi"}	Clinical pharmacology and therapeutics	6	\N	\N	2003	12811365	\N	\N	\N	2	f	\N
117552	\N	Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.	{"Chung Jae-Yong","Cho Joo-Youn","Yu Kyung-Sang","Kim Jung-Ryul","Oh Dal-Seok","Jung Hye-Ryung","Lim Kyoung-Soo","Moon Ki-Ho","Shin Sang-Goo","Jang In-Jin"}	Clinical pharmacology and therapeutics	10	\N	\N	2005	16198653	\N	\N	\N	2	f	\N
117557	\N	Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.	{"Han Ji-Youn","Lim Hyeong-Seok","Shin Eun Soon","Yoo Yeon-Kyeong","Park Yong Hoon","Lee Jong-Eun","Kim Heung Tae","Lee Jin Soo"}	Lung cancer (Amsterdam, Netherlands)	1	\N	\N	2008	17766002	\N	\N	\N	2	f	\N
117561	\N	Duplex pyrosequencing assay of the 388A>G and 521T>C SLCO1B1 polymorphisms in three Asian populations.	{"Kim Eun-Young","Cho Doo-Yeoun","Shin Ho-Jung","Lee Sang-Seop","Shon Ji-Hong","Shin Jae-Gook","Shin Sang-Goo"}	Clinica chimica acta; international journal of clinical chemistry	2	\N	\N	2008	17996736	\N	\N	\N	2	f	\N
117566	\N	Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15.	{"Kim Su-Ryang","Saito Yoshiro","Sai Kimie","Kurose Kouichi","Maekawa Keiko","Kaniwa Nahoko","Ozawa Shogo","Kamatani Naoyuki","Shirao Kuniaki","Yamamoto Noboru","Hamaguchi Tetsuya","Kunitoh Hideo","Ohe Yuichiro","Yamada Yasuhide","Tamura Tomohide","Yoshida Teruhiko","Minami Hironobu","Ohtsu Atsushi","Saijo Nagahiro","Sawada Jun-ichi"}	Drug metabolism and pharmacokinetics	12	\N	\N	2007	18159134	\N	\N	\N	2	f	\N
117568	\N	Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.	{"Miura Masatomo","Kagaya Hideaki","Satoh Shigeru","Inoue Kazuyuki","Saito Mitsuru","Habuchi Tomonori","Suzuki Toshio"}	Therapeutic drug monitoring	10	\N	\N	2008	18695635	\N	\N	\N	2	f	\N
117580	\N	Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.	{"Pasanen Marja K","Backman Janne T","Neuvonen Pertti J","Niemi Mikko"}	European journal of clinical pharmacology	6	\N	\N	2006	16758257	\N	\N	\N	2	f	\N
117583	\N	The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics.	{"Vormfelde S V","Toliat M R","Schirmer M","Meineke I","Nürnberg P","Brockmöller J"}	Clinical pharmacology and therapeutics	6	\N	\N	2008	18043684	\N	\N	\N	2	f	\N
117589	\N	The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.	{"Picard N","Yee S W","Woillard J-B","Lebranchu Y","Le Meur Y","Giacomini K M","Marquet P"}	Clinical pharmacology and therapeutics	1	\N	\N	2010	19890249	\N	\N	\N	2	f	\N
117591	\N	Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction.	{"Peters Bas J M","Rodin Andrei S","Klungel Olaf H","van Duijn Cornelia M","Stricker Bruno H Ch","van't Slot Ruben","de Boer Anthonius","Maitland-van der Zee Anke-Hilse"}	Pharmacogenomics	8	\N	\N	2010	20712525	\N	\N	\N	2	f	\N
117593	\N	Organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3: genetic variability and haplotype analysis in white Canadians.	{"Boivin Andrée-Anne","Cardinal Héloïse","Barama Azemi","Pichette Vincent","Hébert Marie-Josée","Roger Michel"}	Drug metabolism and pharmacokinetics	0	\N	\N	2010	20877131	\N	\N	\N	2	f	\N
115070	\N	Gene mutation of thiopurine S-methyltransferase in Uygur Chinese.	{"Zhang Jian-Ping","Guan Yong-Yuan","Xu An-Long","Zhou Shu-Feng","Wu Jue-Heng","Wei Hong","Huang Min"}	European journal of clinical pharmacology	3	\N	\N	2004	14985891	\N	\N	\N	2	f	\N
114883	\N	An integrated map of structural variation in 2,504 human genomes.	{"Sudmant Peter H","Rausch Tobias","Gardner Eugene J","Handsaker Robert E","Abyzov Alexej","Huddleston John","Zhang Yan","Ye Kai","Jun Goo","Fritz Markus Hsi-Yang","Konkel Miriam K","Malhotra Ankit","Stütz Adrian M","Shi Xinghua","Casale Francesco Paolo","Chen Jieming","Hormozdiari Fereydoun","Dayama Gargi","Chen Ken","Malig Maika","Chaisson Mark J P","Walter Klaudia","Meiers Sascha","Kashin Seva","Garrison Erik","Auton Adam","Lam Hugo Y K","Mu Xinmeng Jasmine","Alkan Can","Antaki Danny","Bae Taejeong","Cerveira Eliza","Chines Peter","Chong Zechen","Clarke Laura","Dal Elif","Ding Li","Emery Sarah","Fan Xian","Gujral Madhusudan","Kahveci Fatma","Kidd Jeffrey M","Kong Yu","Lameijer Eric-Wubbo","McCarthy Shane","Flicek Paul","Gibbs Richard A","Marth Gabor","Mason Christopher E","Menelaou Androniki","Muzny Donna M","Nelson Bradley J","Noor Amina","Parrish Nicholas F","Pendleton Matthew","Quitadamo Andrew","Raeder Benjamin","Schadt Eric E","Romanovitch Mallory","Schlattl Andreas","Sebra Robert","Shabalin Andrey A","Untergasser Andreas","Walker Jerilyn A","Wang Min","Yu Fuli","Zhang Chengsheng","Zhang Jing","Zheng-Bradley Xiangqun","Zhou Wanding","Zichner Thomas","Sebat Jonathan","Batzer Mark A","McCarroll Steven A","1000 Genomes Project Consortium","Mills Ryan E","Gerstein Mark B","Bashir Ali","Stegle Oliver","Devine Scott E","Lee Charles","Eichler Evan E","Korbel Jan O"}	Nature	10	\N	\N	2015	26432246	\N	\N	\N	2	f	\N
114887	\N	Polymorphism of the thiopurine S-methyltransferase gene in African-Americans.	{"Hon Y Y","Fessing M Y","Pui C H","Relling M V","Krynetski E Y","Evans W E"}	Human molecular genetics	2	\N	\N	1999	9931346	\N	\N	\N	2	f	\N
116483	\N	Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations.	{"Maeda Hiromichi","Hazama Shoichi","Shavkat Abdiev","Okamoto Ken","Oba Koji","Sakamoto Junichi","Takahashi Kenichi","Oka Masaki","Nakamura Daisuke","Tsunedomi Ryouichi","Okayama Naoko","Mishima Hideyuki","Kobayashi Michiya"}	Molecular diagnosis & therapy	6	\N	\N	2014	24453052	\N	\N	\N	2	f	\N
114939	\N	The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations.	{"Collie-Duguid E S","Pritchard S C","Powrie R H","Sludden J","Collier D A","Li T","McLeod H L"}	Pharmacogenetics	2	\N	\N	1999	10208641	\N	\N	\N	2	f	\N
114941	\N	Prevalence of TPMT polymorphism in Indian patients requiring immunomodulator therapy and its clinical significance.	{"Davavala Sandeep Kirit","Desai Devendra C","Abraham Philip","Ashavaid Tester","Joshi Anand","Gupta Tarun"}	Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology	1	\N	\N	2014	23996738	\N	\N	\N	2	f	\N
114943	\N	Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine.	{"Desire Salamun","Balasubramanian Poonkuzhali","Bajel Ashish","George Biju","Viswabandya Auro","Mathews Vikram","Srivastava Alok","Chandy Mammen"}	Medical oncology (Northwood, London, England)	12	\N	\N	2010	19830600	\N	\N	\N	2	f	\N
114947	\N	Application of SNaPshot for analysis of thiopurine methyltransferase gene polymorphism.	{"Kapoor Gauri","Maitra Arindam",Somlata,"Brahmachari Vani"}	The Indian journal of medical research	5	\N	\N	2009	19675376	\N	\N	\N	2	f	\N
114951	\N	Thiopurine methyltransferase polymorphisms in a multiracial asian population and children with acute lymphoblastic leukemia.	{"Kham S K Y","Tan P L","Tay A H N","Heng C K","Yeoh A E J","Quah Thuan-Chong"}	Journal of pediatric hematology/oncology	0	\N	\N	2002	12142782	\N	\N	\N	2	f	\N
114953	\N	Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore.	{"Kham Shirley Kow Yin","Soh Chin Kok","Liu Te Chih","Chan Yiong Huak","Ariffin Hany","Tan Poh Lin","Yeoh Allen Eng Juh"}	European journal of clinical pharmacology	4	\N	\N	2008	18193212	\N	\N	\N	2	f	\N
114957	\N	Thiopurine methyltransferase polymorphisms in children with acute lymphoblastic leukemia.	{"Linga Vijay Gandhi","Patchva Dorra Babu","Mallavarapu Krishna Mohan","Tulasi Venkata","Kalpathi Krishnamani Iyer","Pillai Ashok","Gundeti Sadashivudu","Rajappa Senthil J","Digumarti Raghunadharao"}	Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology	10	\N	\N	2014	25538405	\N	\N	\N	2	f	\N
114959	\N	Genotyping of eight polymorphic genes encoding drug-metabolizing enzymes and transporters using a customized oligonucleotide array.	{"Lu Yi","Kham Shirley Kow-Yin","Foo Toon-Chai","Ariffin Hany","Hany Ariffin","Quah Thuan-Chong","Yeoh Allen Eng-Juh"}	Analytical biochemistry	1	\N	\N	2007	17113562	\N	\N	\N	2	f	\N
114961	\N	Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians.	{"Marinaki Anthony M","Arenas Monica","Khan Zubair H","Lewis Cathryn M","Shobowale-Bakre El-Monsor","Escuredo Emilia","Fairbanks Lynette D","Mayberry John F","Wicks Antony C","Ansari Azhar","Sanderson Jeremy","Duley John A"}	Pharmacogenetics	2	\N	\N	2003	12563179	\N	\N	\N	2	f	\N
114965	\N	Inter and intra-ethnic differences in the distribution of the molecular variants of TPMT, UGT1A1 and MDR1 genes in the South Indian population.	{"Umamaheswaran Gurusamy","Krishna Kumar Dhakchinamoorthi","Kayathiri Dhandapani","Rajan Subramanian","Shewade Deepak Gopal","Dkhar Steven Aibor","Manjunath Sajjanavar","Ushakiran Prayaga","Reneega Gangadharan","Ritushree Kukreti","Adithan Chandrasekaran"}	Molecular biology reports	5	\N	\N	2012	22318545	\N	\N	\N	2	f	\N
114998	\N	Genetic polymorphisms of thiopurine S-methyltransferase and 6-mercaptopurine toxicity in Japanese children with acute lymphoblastic leukaemia.	{"Ando M","Ando Y","Hasegawa Y","Sekido Y","Shimokata K","Horibe K"}	Pharmacogenetics	4	\N	\N	2001	11337943	\N	\N	\N	2	f	\N
115000	\N	Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease.	{"Ban Hiromitsu","Andoh Akira","Tanaka Aiko","Tsujikawa Tomoyuki","Sasaki Masaya","Saito Yasuharu","Fujiyama Yoshihide"}	Internal medicine (Tokyo, Japan)	0	\N	\N	2008	18827410	\N	\N	\N	2	f	\N
115004	\N	Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.	{"Cao Qian","Zhu Qin","Shang Yan","Gao Min","Si Jianmin"}	Digestion	0	\N	\N	2009	19252404	\N	\N	\N	2	f	\N
115006	\N	Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations.	{"Chang Jan-Gowth","Lee Long-Shyong","Chen Chih-Mei","Shih Mu-Chin","Wu Mei-Chen","Tsai Fuu-Jen","Liang Der-Cheng"}	Pharmacogenetics	4	\N	\N	2002	11927834	\N	\N	\N	2	f	\N
115009	\N	Association of thiopurine methyltransferase status with azathioprine side effects in Chinese patients with systemic lupus erythematosus.	{"Chen Dongying","Lian Fan","Yuan Shiwen","Wang Yixi","Zhan Zhongping","Ye Yujin","Qiu Qian","Xu Hanshi","Liang Liuqin","Yang Xiuyan"}	Clinical rheumatology	4	\N	\N	2014	24322830	\N	\N	\N	2	f	\N
115014	\N	Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population.	{"Hiratsuka M","Inoue T","Omori F","Agatsuma Y","Mizugaki M"}	Mutation research	3	\N	\N	2000	10751626	\N	\N	\N	2	f	\N
115016	\N	Frequency of thiopurine S-methyltransferase genetic variation in Thai children with acute leukemia.	{"Hongeng S","Sasanakul W","Chuansumrit A","Pakakasama S","Chattananon A","Hathirat P"}	Medical and pediatric oncology	10	\N	\N	2000	11025471	\N	\N	\N	2	f	\N
115020	\N	Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs.	{"Jung Yoon Suk","Cheon Jae Hee","Park Jae Jun","Moon Chang Mo","Kim Eun Soo","Lee Jin Ha","Kim Seung Won","Kim Jae Hak","Hong Sung Pil","Kim Tae Il","Kim Won Ho"}	Journal of human genetics	2	\N	\N	2010	19960028	\N	\N	\N	2	f	\N
115024	\N	Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study.	{"Kim Jae Hak","Cheon Jae Hee","Hong Seong Soo","Eun Chang Soo","Byeon Jeong-Sik","Hong Sung Yi","Kim Bo-Young","Kwon Soon-Ho","Kim Seung Won","Han Dong Soo","Yang Suk-Kyun","Kim Won Ho"}	Journal of clinical gastroenterology	0	\N	\N	2010	20308917	\N	\N	\N	2	f	\N
115026	\N	Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism.	{"Kim Hyery","Kang Hyoung Jin","Kim Hyo Jeong","Jang Mi Kyung","Kim Nam Hee","Oh Yongtaek","Han Byoung-Don","Choi Ji-Yeob","Kim Chul Woo","Lee Ji Won","Park Kyung Duk","Shin Hee Young","Ahn Hyo Seop"}	PloS one	0	\N	\N	2012	23029095	\N	\N	\N	2	f	\N
115028	\N	Complete sequence-based screening of TPMT variants in the Korean population.	{"Kim Hyun-Young","Lee Soo Hyun","Lee Mi-Na","Kim Jong-Won","Kim Young-Ho","Kim Mi Jin","Lee Yoo Min","Kang Ben","Choe Yon Ho","Lee Na Hee","Kim Dong Hwan","Yoo Keon Hee","Sung Ki Woong","Lee Soo-Youn","Koo Hong Hoe"}	Pharmacogenetics and genomics	3	\N	\N	2015	25564374	\N	\N	\N	2	f	\N
115032	\N	Frequency distribution of thiopurine S-methyltransferase activity in red blood cells of a healthy Japanese population.	{"Kubota Takahiro","Nishida Akihito","Takeuchi Ken","Iida Takayuki","Yokota Hiromitsu","Higashi Katsumi","Nakahara Kazuhiko","Hanai Hiroyuki","Iga Tatsuji"}	Therapeutic drug monitoring	6	\N	\N	2004	15167635	\N	\N	\N	2	f	\N
115036	\N	Duplex pyrosequencing of the TPMT*3C and TPMT*6 alleles in Korean and Vietnamese populations.	{"Lee Sang Seop","Kim Woo-Young","Jang Yin-Jin","Shin Jae-Gook"}	Clinica chimica acta; international journal of clinical chemistry	12	\N	\N	2008	18775689	\N	\N	\N	2	f	\N
115039	\N	Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine.	{"Lee Mi-Na","Kang Ben","Choi So Yoon","Kim Mi Jin","Woo Sook Young","Kim Jong-Won","Choe Yon Ho","Lee Soo-Youn"}	Inflammatory bowel diseases	5	\N	\N	2015	25851563	\N	\N	\N	2	f	\N
115044	\N	Molecular analysis of the thiopurine S-methyltransferase alleles in Bolivians and Tibetans.	{"Lu H-F","Shih M-C","Hsueh S-C","Chen C-M","Chang J-Y","Chang J-G"}	Journal of clinical pharmacy and therapeutics	10	\N	\N	2005	16164497	\N	\N	\N	2	f	\N
115050	\N	Thiopurine methyltransferase genotype and phenotype status in Japanese patients with systemic lupus erythematosus.	{"Okada Yuko","Nakamura Katsunori","Kodama Tomoko","Ueki Kazue","Tsukada Yoshito","Maezawa Akira","Tsukamoto Norifumi","Nojima Yoshihisa","Ishizaki Takashi","Horiuchi Ryuya","Yamamoto Koujirou"}	Biological & pharmaceutical bulletin	11	\N	\N	2005	16272700	\N	\N	\N	2	f	\N
115052	\N	Accuracy of genotyping using the TaqMan PCR assay for single nucleotide polymorphisms responsible for thiopurine sensitivity in Japanese patients with inflammatory bowel disease.	{"Osaki Rie","Imaeda Hirotsugu","Ban Hiromitsu","Aomatsu Tomoki","Bamba Shigeki","Tsujikawa Tomoyuki","Sasaki Masaya","Fujiyama Yoshihide","Andoh Akira"}	Experimental and therapeutic medicine	9	\N	\N	2011	22977575	\N	\N	\N	2	f	\N
115054	\N	TPMT genotype and its clinical implication in renal transplant recipients with azathioprine treatment.	{"Song D-K","Zhao J","Zhang L-R"}	Journal of clinical pharmacy and therapeutics	12	\N	\N	2006	17176368	\N	\N	\N	2	f	\N
115056	\N	Thiopurine S-methyltransferase genetic polymorphism in the Thai population.	{"Srimartpirom Somrudee","Tassaneeyakul Wongwiwat","Kukongviriyapan Veerapol","Tassaneeyakul Wichittra"}	British journal of clinical pharmacology	7	\N	\N	2004	15206995	\N	\N	\N	2	f	\N
115058	\N	Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease.	{"Takatsu Noritaka","Matsui Toshiyuki","Murakami Yuji","Ishihara Hiroshi","Hisabe Takashi","Nagahama Takashi","Maki Shinichirou","Beppu Takahiro","Takaki Yasuhiro","Hirai Fumihito","Yao Kenshi"}	Journal of gastroenterology and hepatology	7	\N	\N	2009	19682195	\N	\N	\N	2	f	\N
115060	\N	Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases.	{"Tamori Akihiro","Shinzaki Mayumi","Kosaka Saori","Hayashi Takehiro","Iwai Shuji","Enomoto Masaru","Habu Daiki","Sakaguchi Hiroki","Kawada Norifumi","Hino Masayuki","Shiomi Susumu","Nishiguchi Shuhei"}	Liver international : official journal of the International Association for the Study of the Liver	2	\N	\N	2007	17241387	\N	\N	\N	2	f	\N
115064	\N	Impact of the heterozygous TPMT*1/*3C genotype on azathioprine-induced myelosuppression in kidney transplant recipients in Thailand.	{"Vannaprasaht Suda","Angsuthum Susothorn","Avihingsanon Yingyos","Sirivongs Dhavee","Pongskul Cholatip","Makarawate Pattarapong","Praditpornsilpa Kearkiat","Tassaneeyakul Wongwiwat","Tassaneeyakul Wichittra"}	Clinical therapeutics	7	\N	\N	2009	19695401	\N	\N	\N	2	f	\N
115066	\N	Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients.	{"Xin Hua-Wen","Xiong Hui","Wu Xiao-Chun","Li Qing","Xiong Lei","Yu Ai-Rong"}	European journal of clinical pharmacology	3	\N	\N	2009	19048245	\N	\N	\N	2	f	\N
115072	\N	Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: a comparison of Han and Yao ethnic groups.	{"Zhang Jian-ping","Guan Yong-yuan","Wu Jue-heng","Xu An-long","Zhou Shufeng","Huang Min"}	British journal of clinical pharmacology	8	\N	\N	2004	15255798	\N	\N	\N	2	f	\N
115080	\N	Efficient screening method of the thiopurine methyltransferase polymorphisms for patients considering taking thiopurine drugs in a Chinese Han population in Henan Province (central China).	{"Zhang Li-Rong","Song Dong-Kui","Zhang Wei","Zhao Jun","Jia Lin-Jing","Xing Dong-Liang"}	Clinica chimica acta; international journal of clinical chemistry	2	\N	\N	2007	16952345	\N	\N	\N	2	f	\N
116485	\N	Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing.	{"Saeki Mayumi","Saito Yoshiro","Jinno Hideto","Tohkin Masahiro","Kurose Kouichi","Kaniwa Nahoko","Komamura Kazuo","Ueno Kazuyuki","Kamakura Shiro","Kitakaze Masafumi","Ozawa Shogo","Sawada Jun-Ichi"}	Clinical chemistry	7	\N	\N	2003	12816917	\N	\N	\N	2	f	\N
115140	\N	Thiopurine methyltransferase pharmacogenetics: alternative molecular diagnosis and preliminary data from Northern Portugal.	{"Alves S","Prata M J","Ferreira F","Amorim A"}	Pharmacogenetics	4	\N	\N	1999	10376773	\N	\N	\N	2	f	\N
115144	\N	Thiopurine methyltransferase alleles in British and Ghanaian populations.	{"Ameyaw M M","Collie-Duguid E S","Powrie R H","Ofori-Adjei D","McLeod H L"}	Human molecular genetics	2	\N	\N	1999	9931345	\N	\N	\N	2	f	\N
115148	\N	Thiopurine S-Methyltransferase gene polymorphisms in a healthy Slovak population and pediatric patients with inflammatory bowel disease.	{"Chocholova Alica","Soltysova Andrea","Minarik Gabriel","Cierna Iveta","Sufliarska Sabina","Mladosievicova Beata"}	Nucleosides, nucleotides & nucleic acids	0	\N	\N	2013	23581716	\N	\N	\N	2	f	\N
115152	\N	Thiopurine S-methyltransferase phenotype-genotype correlation in children with acute lymphoblastic leukemia.	{"Chrzanowska Maria","Kuehn Marta","Januszkiewicz-Lewandowska Danuta","Kurzawski Mateusz","Droździk Marek"}	Acta poloniae pharmaceutica	0	\N	\N	2012	22594254	\N	\N	\N	2	f	\N
115155	\N	Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls.	{"Corominas H","Domènech M","González D","Diaz C","Roca M","García-González M A","Peña S","Baiget M"}	The American journal of gastroenterology	9	\N	\N	2000	11007234	\N	\N	\N	2	f	\N
115158	\N	Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients?	{"Corominas H","Domènech M","Laíz A","Gich I","Geli C","Díaz C","de Cuevillas F","Moreno M","Vázquez G","Baiget M"}	Rheumatology (Oxford, England)	1	\N	\N	2003	12509611	\N	\N	\N	2	f	\N
115162	\N	Prevalence of mutations in thiopurine S-methyltransferase gene among Slovak IBD patients.	{"Desatova B","Hlavaty T","Balakova D","Pav I","Celec P","Gregus M","Zakuciova M","Hlista M","Horakova M","Kadasi L","Huorka M","Batovsky M"}	Bratislavske lekarske listy	0	\N	\N	2013	23731044	\N	\N	\N	2	f	\N
115164	\N	Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders.	{"Di Salvo Angela","Fabiano Carmelo","Mannara Vincenza","Dimarco Mariangela","Orlando Ambrogio","Affronti Marco","Macaluso Fabio Salvatore","Cottone Mario"}	Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver	12	\N	\N	2016	27665263	\N	\N	\N	2	f	\N
115166	\N	Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.	{"Dokmanovic Lidija","Urosevic Jelena","Janic Dragana","Jovanovic Nada","Petrucev Branka","Tosic Natasa","Pavlovic Sonja"}	Therapeutic drug monitoring	12	\N	\N	2006	17164697	\N	\N	\N	2	f	\N
115170	\N	Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.	{"Gazouli M","Pachoula I","Panayotou I","Mantzaris G","Syriopoulou V P","Goutas N","Vlachodimitropoulos D","Anagnou N P","Roma-Giannikou E"}	Journal of clinical pharmacy and therapeutics	2	\N	\N	2010	20175817	\N	\N	\N	2	f	\N
115172	\N	Pyrosequencing of TPMT alleles in a general Swedish population and in patients with inflammatory bowel disease.	{"Haglund Sofie","Lindqvist Malin","Almer Sven","Peterson Curt","Taipalensuu Jan"}	Clinical chemistry	2	\N	\N	2004	14656901	\N	\N	\N	2	f	\N
115174	\N	Thiopurine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events.	{"Heckmann Jeannine M","Lambson Elisabetta M T","Little Francesca","Owen Elizabeth P"}	Journal of the neurological sciences	4	\N	\N	2005	15792824	\N	\N	\N	2	f	\N
115179	\N	Frequency distribution of thiopurine S-methyltransferase alleles in a polish population.	{"Kurzawski Mateusz","Gawronska-Szklarz Barbara","Drozdzik Marek"}	Therapeutic drug monitoring	10	\N	\N	2004	15385838	\N	\N	\N	2	f	\N
115181	\N	The impact of thiopurine s-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients.	{"Kurzawski Mateusz","Dziewanowski Krzysztof","Gawrońska-Szklarz Barbara","Domański Leszek","Droździk Marek"}	Therapeutic drug monitoring	8	\N	\N	2005	16044099	\N	\N	\N	2	f	\N
115185	\N	High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease.	{"Larussa Tiziana","Suraci Evelina","Lentini Margherita","Nazionale Immacolata","Gallo Luigia","Abenavoli Ludovico","Imeneo Maria","Costanzo Francesco Saverio","Cuda Giovanni","Luzza Francesco"}	European journal of internal medicine	4	\N	\N	2012	22385887	\N	\N	\N	2	f	\N
115189	\N	Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway.	{"Loennechen T","Utsi E","Hartz I","Lysaa R","Kildalsen H","Aarbakke J"}	Clinical pharmacology and therapeutics	8	\N	\N	2001	11503013	\N	\N	\N	2	f	\N
115194	\N	Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals.	{"McLeod H L","Pritchard S C","Githang'a J","Indalo A","Ameyaw M M","Powrie R H","Booth L","Collie-Duguid E S"}	Pharmacogenetics	12	\N	\N	1999	10634140	\N	\N	\N	2	f	\N
115196	\N	Thiopurine S-methyltransferase pharmacogenetics: genotype to phenotype correlation in the Slovenian population.	{"Milek M","Murn J","Jaksic Z","Lukac Bajalo J","Jazbec J","Mlinaric Rascan I"}	Pharmacology	0	\N	\N	2006	16691038	\N	\N	\N	2	f	\N
115198	\N	Rapid genotyping of common deficient thiopurine S-methyltransferase alleles using the DNA-microchip technique.	{"Nasedkina Tatyana V","Fedorova Olga E","Glotov Andrei S","Chupova Natalia V","Samochatova Elena V","Maiorova Olga A","Zemlyakova Valeria V","Roudneva Anastasia E","Chudinov Alexander V","Yurasov Roman A","Kozhekbaeva Janna M","Barsky Victor E","Krynetskiy Eugene Y","Krynetskaia Natalia F","Cheng Cheng","Ribeiro Raul C","Evans William E","Roumyantsev Alexander G","Zasedatelev Alexander S"}	European journal of human genetics : EJHG	9	\N	\N	2006	16724002	\N	\N	\N	2	f	\N
115202	\N	Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects.	{"Rossi A M","Bianchi M","Guarnieri C","Barale R","Pacifici G M"}	European journal of clinical pharmacology	4	\N	\N	2001	11372592	\N	\N	\N	2	f	\N
115206	\N	TPMT genetic variations in populations of the Russian Federation.	{"Samochatova Elena V","Chupova Natalia V","Rudneva Anastassia","Makarova Olga","Nasedkina Tatyana V","Fedorova Olga E","Glotov Andrei S","Kozhekbaeva Zh","Maiorova Olga A","Roumyantsev Alexander G","Krynetski Eugene Y","Krynetskaia Natalia F","Evans William E","Ribeiro Raul C"}	Pediatric blood & cancer	2	\N	\N	2009	19034904	\N	\N	\N	2	f	\N
115208	\N	Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants.	{"Schaeffeler Elke","Fischer Christine","Brockmeier Dierk","Wernet Dorothee","Moerike Klaus","Eichelbaum Michel","Zanger Ulrich M","Schwab Matthias"}	Pharmacogenetics	7	\N	\N	2004	15226673	\N	\N	\N	2	f	\N
115210	\N	Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function.	{"Schaeffeler Elke","Eichelbaum Michel","Reinisch Walter","Zanger Ulrich M","Schwab Matthias"}	Human mutation	9	\N	\N	2006	16917910	\N	\N	\N	2	f	\N
115212	\N	Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity.	{"Serpe Loredana","Calvo Pier Luigi","Muntoni Elisabetta","D'Antico Sergio","Giaccone Mario","Avagnina Alessandra","Baldi Maurizio","Barbera Cristiana","Curti Franco","Pera Angelo","Eandi Mario","Zara Gian Paolo","Canaparo Roberto"}	Pharmacogenomics	11	\N	\N	2009	19891552	\N	\N	\N	2	f	\N
115216	\N	Polymorphisms of the TPMT gene in the Czech healthy population and patients with inflammatory bowel disease.	{"Slanar Ondrej","Bortlík Martin","Buzková Helena","Donoval Robert","Pechandová Kristina","Sebesta Ivan","Lukás Milan","Perlík Frantisek"}	Nucleosides, nucleotides & nucleic acids	6	\N	\N	2008	18600549	\N	\N	\N	2	f	\N
115218	\N	Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population.	{"Spire-Vayron de la Moureyre C","Debuysere H","Mastain B","Vinner E","Marez D","Lo Guidice J M","Chevalier D","Brique S","Motte K","Colombel J F","Turck D","Noel C","Flipo R M","Pol A","Lhermitte M","Lafitte J J","Libersa C","Broly F"}	British journal of pharmacology	10	\N	\N	1998	9831928	\N	\N	\N	2	f	\N
115220	\N	TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects.	{"Steponaitiene Ruta","Kupcinskas Juozas","Survilaite Santa","Varkalaite Greta","Jonaitis Laimas","Kiudelis Gediminas","Denapiene Goda","Valantinas Jonas","Skieceviciene Jurgita","Kupcinskas Limas"}	Advances in medical sciences	3	\N	\N	2016	26674571	\N	\N	\N	2	f	\N
115224	\N	Genetic analyses of thiopurine methyltransferase polymorphisms in Greenlandic and Danish populations.	{"Toft Nina","Nygaard Ulrikka","Gregers Jannie","Schmiegelow Kjeld"}	Acta paediatrica (Oslo, Norway : 1992)	12	\N	\N	2006	17129980	\N	\N	\N	2	f	\N
115252	\N	Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.	{"Farfan Mauricio J","Salas Carolina","Canales Cristina","Silva Felipe","Villarroel Milena","Kopp Katherine","Torres Juan P","Santolaya María E","Morales Jorge"}	BMC cancer	4	\N	\N	2014	24774509	\N	\N	\N	2	f	\N
115256	\N	Analysis of Thiopurine S-Methyltransferase Deficient Alleles in Acute Lymphoblastic Leukemia Patients in Mexican Patients.	{"Jiménez-Morales Silvia","Ramírez-Florencio Mireya","Mejía-Aranguré Juan Manuel","Núñez-Enríquez Juan Carlos","Bekker-Mendez Carolina","Torres-Escalante José Luis","Flores-Lujano Janet","Jiménez-Hernández Elva","Del Carmen Rodríguez-Zepeda María","Leal Yelda A","González-Montalvo Pablo Miguel","Pantoja-Guillen Francisco","Peñaloza-Gonzalez José Gabriel","Gutiérrez-Juárez Erick Israel","Núñez-Villegas Nora Nancy","Pérez-Saldivar Maria Luisa","Guerra-Castillo Francisco Xavier","Flores-Villegas Luz Victoria","Ramos-Cervantes María Teresa","Fragoso José Manuel","García-Escalante María Guadalupe","Del Carmen Pinto-Escalante Doris","Ramírez-Bello Julián","Hidalgo-Miranda Alfredo"}	Archives of medical research	11	\N	\N	2016	28476189	\N	\N	\N	2	f	\N
115259	\N	High frequency of mutant thiopurine S-methyltransferase genotypes in Mexican patients with systemic lupus erythematosus and rheumatoid arthritis.	{"Ramirez-Florencio Mireya","Jiménez-Morales Silvia","Barbosa-Cobos Rosa Elda","López-Cano Daniela Josabeth","Ramírez-Bello Julian"}	Clinical rheumatology	4	\N	\N	2018	29264794	\N	\N	\N	2	f	\N
115261	\N	Pharmacogenetic screening of N-acetyltransferase 2, thiopurine s-methyltransferase, and 5,10-methylene-tetrahydrofolate reductase polymorphisms in Northwestern Mexicans.	{"Ramos Marco A","Mares Rosa E","Avalos Erick D","Hernández Anaid","Hernández Rogelio","Lameda Rodrigo","Malváez Analleli E","Rodríguez Carla A","Rodríguez Rosario"}	Genetic testing and molecular biomarkers	5	\N	\N	2011	21254844	\N	\N	\N	2	f	\N
115265	\N	Thiopurine S-methyltransferase gene (TMPT) polymorphisms in a Mexican population of healthy individuals and leukemic patients.	{"Taja-Chayeb Lucia","Vidal-Millán Silvia","Gutiérrez Olga","Ostrosky-Wegman Patricia","Dueñas-González Alfonso","Candelaria Myrna"}	Medical oncology (Northwood, London, England)	0	\N	\N	2008	18188716	\N	\N	\N	2	f	\N
115267	\N	Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia.	{"Albayrak Meryem","Konyssova Uljan","Kaya Zuhre","Gursel Turkiz","Guntekin Sezen","Percin E Ferda","Kocak Ulker"}	Cancer chemotherapy and pharmacology	11	\N	\N	2011	21400026	\N	\N	\N	2	f	\N
115271	\N	Frequency of thiopurine S-methyltransferase (TPMT) alleles in southeast Iranian population.	{"Bahari Ali","Hashemi Mohammad","Bari Zohreh","Moazeni-Roodi Abdolkarim","Kaykhaei Mahmoud-Ali","Narouie Behzad"}	Nucleosides, nucleotides & nucleic acids	3	\N	\N	2010	20408054	\N	\N	\N	2	f	\N
115278	\N	Genetic analysis of thiopurine methyltransferase polymorphism in the Jordanian population.	{"Hakooz Nancy","Arafat Tawfiq","Payne Debbie","Ollier William","Pushpakom Sudeep","Andrews Julie","Newman William"}	European journal of clinical pharmacology	10	\N	\N	2010	20521035	\N	\N	\N	2	f	\N
115283	\N	Evaluating frequencies of thiopurine S-methyl transferase (TPMT) variant alleles in Israeli ethnic subpopulations using DNA analysis.	{"Ronen Ofri","Cohen Sara Bar","Rund Deborah"}	The Israel Medical Association journal : IMAJ	12	\N	\N	2010	21348397	\N	\N	\N	2	f	\N
115287	\N	The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia.	{"Tumer Tugba Boyunegmez","Ulusoy Gulen","Adali Orhan","Sahin Gurses","Gozdasoglu Sevgi","Arinç Emel"}	American journal of hematology	10	\N	\N	2007	17617792	\N	\N	\N	2	f	\N
115289	\N	Genetic polymorphisms of NQO1, CYP1A1 and TPMT and susceptibility to acute lymphoblastic leukemia in a Tunisian population.	{"Ouerhani Slah","Cherif Nouha","Bahri Ikbel","Safra Ines","Menif Samia","Abbes Salem"}	Molecular biology reports	2	\N	\N	2013	23065291	\N	\N	\N	2	f	\N
115293	\N	Allele frequency of inosine triphosphate pyrophosphatase (ITPA) and thiopurine-S-methyl transferase (TPMT) genes in the Tunisian population.	{"Melaouhia Salma","Fékih Monia","Garat Anne","Allorge Delphine","Ferchichi Henda","Klouz Anis","Boubaker Jalel","Broly Franck","Lakhal Mohamed"}	Clinics and research in hepatology and gastroenterology	4	\N	\N	2012	22225964	\N	\N	\N	2	f	\N
115297	\N	Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population.	{"Hamdy Samar I","Hiratsuka Masahiro","Narahara Kaori","Endo Naomi","El-Enany Mervat","Moursi Nadia","Ahmed Mohammed S-E","Mizugaki Michinao"}	British journal of clinical pharmacology	6	\N	\N	2003	12814450	\N	\N	\N	2	f	\N
115299	\N	Polymorphisms of the thiopurine S-methyltransferase gene among the Libyan population.	{"Zeglam Hamza Ben","Benhamer Abdrazak","Aboud Adel","Rtemi Haitem","Mattardi Meftah","Saleh Saleh Suleiman","Bashein Abdullah","Enattah Nabil"}	The Libyan journal of medicine	0	\N	\N	2015	25819542	\N	\N	\N	2	f	\N
115306	\N	Analysis of thiopurine S-methyltransferase phenotype-genotype in a Tunisian population with Crohn's disease.	{"Ben Salah Lynda","Belkhiria el Haj Amor Mouna","Chbili Chahra","Khlifi Saida","Fathallah Neila","Bougmiza Iheb","Ben Jazia Elhem","Houdret Nicole","Ben Salem Chaker","Saguem Saad"}	European journal of drug metabolism and pharmacokinetics	12	\N	\N	2013	23553048	\N	\N	\N	2	f	\N
115319	\N	Influence of ethnicity on pharmacogenetic variation in the Ghanaian population.	{"Yen-Revollo J L","Van Booven D J","Peters E J","Hoskins J M","Engen R M","Kannall H D","Ofori-Adjei D","McLeod H L","Marsh S"}	The pharmacogenomics journal	12	\N	\N	2009	19546880	\N	\N	\N	2	f	\N
116461	\N	Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.	{"Ribaudo Heather J","Daar Eric S","Tierney Camlin","Morse Gene D","Mollan Katie","Sax Paul E","Fischl Margaret A","Collier Ann C","Haas David W","DS Clinical Trials Group"}	The Journal of infectious diseases	2	\N	\N	2013	23148286	\N	\N	\N	2	f	\N
116463	\N	Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.	{"Johnson Daniel H","Venuto Charles","Ritchie Marylyn D","Morse Gene D","Daar Eric S","McLaren Paul J","Haas David W"}	Pharmacogenetics and genomics	4	\N	\N	2014	24557078	\N	\N	\N	2	f	\N
116467	\N	The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications.	{"Premawardhena A","Fisher C A","Liu Y T","Verma I C","de Silva S","Arambepola M","Clegg J B","Weatherall D J"}	Blood cells, molecules & diseases	0	\N	\N	2003	12850492	\N	\N	\N	2	f	\N
116472	\N	Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia.	{"Teh L K","Hashim H","Zakaria Z A","Salleh M Z"}	The Indian journal of medical research	8	\N	\N	2012	22960892	\N	\N	\N	2	f	\N
116487	\N	Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study.	{"Nishijima Takeshi","Tsuchiya Kiyoto","Tanaka Noriko","Joya Akane","Hamada Yohei","Mizushima Daisuke","Aoki Takahiro","Watanabe Koji","Kinai Ei","Honda Haruhito","Yazaki Hirohisa","Tanuma Junko","Tsukada Kunihisa","Teruya Katsuji","Kikuchi Yoshimi","Oka Shinichi","Gatanaga Hiroyuki"}	The Journal of antimicrobial chemotherapy	12	\N	\N	2014	25151207	\N	\N	\N	2	f	\N
116508	\N	Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians.	{"Köhle Christoph","Möhrle Bernd","Münzel Peter A","Schwab Matthias","Wernet Dorothee","Badary Osama A","Bock Karl Walter"}	Biochemical pharmacology	5	\N	\N	2003	12732365	\N	\N	\N	2	f	\N
116531	\N	Distribution of selected gene polymorphisms of UGT1A1 in a Saudi population.	{"Alkharfy Khalid M","Alghamdi Amal M","Bagulb Khawla M","Al-Jenoobi Fahad I","Al-Mohizea Abdullah M","Al-Muhsen Saleh","Halwani Rabih","Parvez Mohammad K","Al-Dosari Mohammed S"}	Archives of medical science : AMS	8	\N	\N	2013	24049537	\N	\N	\N	2	f	\N
116572	\N	Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.	{"Limdi Nita A","Wadelius Mia","Cavallari Larisa","Eriksson Niclas","Crawford Dana C","Lee Ming-Ta M","Chen Chien-Hsiun","Motsinger-Reif Alison","Sagreiya Hersh","Liu Nianjun","Wu Alan H B","Gage Brian F","Jorgensen Andrea","Pirmohamed Munir","Shin Jae-Gook","Suarez-Kurtz Guilherme","Kimmel Stephen E","Johnson Julie A","Klein Teri E","Wagner Michael J","International Warfarin Pharmacogenetics Consortium"}	Blood	5	\N	\N	2010	20203262	\N	\N	\N	2	f	\N
116605	\N	VKORC1 haplotypes in five East-Asian populations and Indians.	{"Lee Ming Ta Michael","Chen Chien-Hsiun","Chuang Hui-Ping","Lu Liang-Suei","Chou Ching-Heng","Chen Ying-Ting","Liu Chih-Yang","Wen Ming-Shien","Lu Jang-Jih","Chang Chi-Feng","Wu Jer-Yuarn","Chen Yuan-Tsong"}	Pharmacogenomics	10	\N	\N	2009	19842934	\N	\N	\N	2	f	\N
110000	100420	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the context of G6PD Deficiency Genotype	{"Relling Mary V","McDonagh Ellen M","Chang Tamara","Caudle Kelly E","McLeod Howard L","Haidar Cyrine E","Klein Teri","Luzzatto Lucio"}	Clinical pharmacology and therapeutics	5			2014	24787449	PMC4111801	10.1038/clpt.2014.97	\N	3	f	https://files.cpicpgx.org/data/guideline/publication/rasburicase/2014/24787449.pdf
110035	104243	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy.	{"Brown Jacob T","Bishop Jeffrey R","Sangkuhl Katrin","Nurmi Erika L","Mueller Daniel J","Dinh Jean C","Gaedigk Andrea","Klein Teri E","Caudle Kelly E","McCracken James T","de Leon Jose","Steven Leeder J"}	Clinical pharmacology and therapeutics	2			2019	30801677	\N	\N	\N	60	f	https://files.cpicpgx.org/data/guideline/publication/atomoxetine/2019/30801677.pdf
3002041	\N	\N	{"Leonie M Hitchman"}	\N	\N	\N	\N	2022	36313436	\N	\N	\N	1	f	\N
3002063	\N	\N	{"Wendy Y Wang"}	\N	\N	\N	\N	2022	36294714	\N	\N	\N	1	f	\N
3001761	\N	\N	{"Twesigomwe David - see Notes"}	\N	\N	\N	\N	2022	36111505	\N	\N	\N	2	f	\N
110023	100409	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype	{"Clancy John P","Johnson Samuel G","Yee Sook Wah","McDonagh Ellen M","Caudle Kelly E","Klein Teri E","Cannavo Matthew","Giacomini Kathleen M"}	Clinical pharmacology and therapeutics	3			2014	24598717	PMC4026598	10.1038/clpt.2014.54	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/ivacaftor/2014/24598717.pdf
110031	100416	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype	{"Crews K R","Gaedigk A","Dunnenberger H M","Klein T E","Shen D D","Callaghan J T","Kharasch E D","Skaar T C"}	Clinical pharmacology and therapeutics	12			2011	22205192	PMC3289963	10.1038/clpt.2011.287	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/codeine/2012/22205192.pdf
2510456	2405438	Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.	{"Gammal Roseann S","Pirmohamed Munir","Somogyi Andrew A","Morris Sarah A","Formea Christine M","Elchynski Amanda L","Oshikoya Kazeem A","McLeod Howard L","Haidar Cyrine E","Whirl-Carrillo Michelle","Klein Teri E","Caudle Kelly E","Relling Mary V"}	Clinical pharmacology and therapeutics	9	\N	\N	2022	36049896	\N	10.1002/cpt.2735	\N	3	f	https://files.cpicpgx.org/data/guideline/publication/G6PD/2022/36049896.pdf
2675961	\N	Clinician adherence to pharmacogenomics prescribing recommendations in clinical decision support alerts.	{"Nguyen Jenny Q","Crews Kristine R","Moore Ben T","Kornegay Nancy M","Baker Donald K","Hasan Murad","Campbell Patrick K","Dean Shannon M","Relling Mary V","Hoffman James M","Haidar Cyrine E"}	Journal of the American Medical Informatics Association : JAMIA	10	\N	\N	2022	36228116	\N	10.1093/jamia/ocac187	\N	2	t	\N
3070387	100413	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.	{"Bousman Chad A","Stevenson James M","Ramsey Laura B","Sangkuhl Katrin","Hicks J Kevin","Strawn Jeffrey R","Singh Ajeet B","Ruaño Gualberto","Mueller Daniel J","Tsermpini Evangelia Eirini","Brown Jacob T","Bell Gillian C","Leeder J Steven","Gaedigk Andrea","Scott Stuart A","Klein Teri E","Caudle Kelly E","Bishop Jeffrey R"}	Clinical pharmacology and therapeutics	4	\N	\N	2023	37032427	\N	10.1002/cpt.2903	https://files.cpicpgx.org/data/guideline/publication/serotonin_reuptake_inhibitor_antidepressants/2023/37032427.pdf	3	f	https://files.cpicpgx.org/data/guideline/publication/serotonin_reuptake_inhibitor_antidepressants/2023/37032427.pdf
110033	100416	Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update	{"Crews Kristine R","Gaedigk Andrea","Dunnenberger Henry M","Leeder J Steve","Klein Teri E","Caudle Kelly E","Haidar Cyrine E","Shen Danny D","Callaghan John T","Sadhasivam Senthilkumar","Prows Cynthia A","Kharasch Evan D","Skaar Todd C"}	Clinical pharmacology and therapeutics	1			2014	24458010	PMC3975212	10.1038/clpt.2013.254	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/codeine/2014/24458010.pdf
110036	104245	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy.	{"Desta Zeruesenay","Gammal Roseann S","Gong Li","Whirl-Carrillo Michelle","Gaur Aditya H","Sukasem Chonlaphat","Hockings Jennifer","Myers Alan","Swart Marelize","Tyndale Rachel","Masimirembwa Collen","Iwuchukwu Otito F","Chirwa Sanika","Lennox Jeffrey","Gaedigk Andrea","Klein Teri","Haas David W"}	Clinical pharmacology and therapeutics	4			2019	31006110	\N	\N	\N	57	f	https://files.cpicpgx.org/data/guideline/publication/efavirenz/2019/31006110.pdf
110005	100411	Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy	{"Scott S A","Sangkuhl K","Gardner E E","Stein C M","Hulot J-S","Johnson J A","Roden D M","Klein T E","Shuldiner A R"}	Clinical pharmacology and therapeutics	6			2011	21716271	PMC3234301	10.1038/clpt.2011.132	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2011/21716271.pdf
571447	110076	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.	{"Lima John J","Thomas Cameron D","Barbarino Julia","Desta Zeruesenay","Van Driest Sara L","El Rouby Nihal","Johnson Julie A","Cavallari Larisa H","Shakhnovich Valentina","Thacker David L","Scott Stuart A","Schwab Matthias","Uppugunduri Chakradhara Rao S","Formea Christine M","Franciosi James P","Sangkuhl Katrin","Gaedigk Andrea","Klein Teri E","Gammal Roseann S","Furuta Takahisa"}	Clinical pharmacology and therapeutics	8	\N	\N	2020	32770672	\N	10.1002/cpt.2015	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/PPI/2020/32770672.pdf
110001	100410	Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guideline for CYP2C19 and Voriconazole Therapy	{"Moriyama Brad","Obeng Aniwaa Owusu","Barbarino Julia","Penzak Scott R","Henning Stacey A","Scott Stuart A","Agúndez José A G","Wingard John R","McLeod Howard L","Klein Teri E","Cross Shane","Caudle Kelly E","Walsh Thomas J"}	Clinical pharmacology and therapeutics	12			2016	27981572	PMC5474211	10.1002/cpt.583	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/voriconazole/2016/27981572.pdf
571448	110058	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.	{"Theken Katherine N","Lee Craig R","Gong Li","Caudle Kelly E","Formea Christine M","Gaedigk Andrea","Klein Teri E","Agúndez José A G","Grosser Tilo"}	Clinical pharmacology and therapeutics	3	\N	\N	2020	32189324	\N	10.1002/cpt.1830	\N	59	f	https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324.pdf
110028	100411	Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy: 2013 Update	{"Scott Stuart A","Sangkuhl Katrin","Stein C Michael","Hulot Jean-Sébastien","Mega Jessica L","Roden Dan M","Klein Teri E","Sabatine Marc S","Johnson Julie A","Shuldiner Alan R"}	Clinical pharmacology and therapeutics	5			2013	23698643	PMC3748366	10.1038/clpt.2013.105	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2013/23698643.pdf
1608551	100411	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.	{"Lee Craig R","Luzum Jasmine A","Sangkuhl Katrin","Gammal Roseann S","Sabatine Marc S","Stein C Michael","Kisor David F","Limdi Nita A","Lee Yee Ming","Scott Stuart A","Hulot Jean-Sébastien","Roden Dan M","Gaedigk Andrea","Caudle Kelly E","Klein Teri E","Johnson Julie A","Shuldiner Alan R"}	Clinical pharmacology and therapeutics	1	\N	\N	2022	35034351	\N	10.1002/cpt.2526	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2022/35034351.pdf
110030	100425	Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update	{"Johnson Julie A","Caudle Kelly E","Gong Li","Whirl-Carrillo Michelle","Stein C Michael","Scott Stuart A","Lee Ming Ta Michael","Gage Brian F","Kimmel Stephen E","Perera Minoli A","Anderson Jeffrey L","Pirmohamed Munir","Klein Teri E","Limdi Nita A","Cavallari Larisa H","Wadelius Mia"}	Clinical pharmacology and therapeutics	2			2017	28198005	PMC5546947	10.1002/cpt.668	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/warfarin/2017/28198005.pdf
110015	100421	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update	{"Martin Michael A","Hoffman James M","Freimuth Robert R","Klein Teri E","Dong Betty J","Pirmohamed Munir","Hicks J Kevin","Wilkinson Mark R","Haas David W","Kroetz Deanna L"}	Clinical pharmacology and therapeutics	2			2014	24561393	PMC3994233	10.1038/clpt.2014.38	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/abacavir/2014/24561393.pdf
110027	100422	Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing	{"Hershfield M S","Callaghan J T","Tassaneeyakul W","Mushiroda T","Thorn C F","Klein T E","Lee M T M"}	Clinical pharmacology and therapeutics	10			2012	23232549	PMC3564416	10.1038/clpt.2012.209	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/allopurinol/2013/23232549.pdf
110007	100424	Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and peginterferon alpha based regimens	{"Muir Andrew J","Gong Li","Johnson Samuel G","Michael Lee Ming Ta","Williams Marc S","Klein Teri E","Caudle Kelly E","Nelson David R"}	Clinical pharmacology and therapeutics	10			2013	24096968	PMC3904555	10.1038/clpt.2013.203	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/pegintron/2013/24096968.pdf
110014	100421	Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing	{"Martin M A","Klein T E","Dong B J","Pirmohamed M","Haas D W","Kroetz D L"}	Clinical pharmacology and therapeutics	2			2012	22378157	PMC3374459	10.1038/clpt.2011.355	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/abacavir/2012/22378157.pdf
110026	100428	Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update.	{"Relling Mary V","Schwab Matthias","Whirl-Carrillo Michelle","Suarez-Kurtz Guilherme","Pui Ching-Hon","Stein Charles M","Moyer Ann M","Evans William E","Klein Teri E","Antillon-Klussmann Federico Guillermo","Caudle Kelly E","Kato Motohiro","Yeoh Allen E J","Schmiegelow Kjeld","Yang Jun J"}	Clinical pharmacology and therapeutics	11			2018	30447069	\N	\N	\N	60	f	https://files.cpicpgx.org/data/guideline/publication/thiopurines/2018/30447069.pdf
110008	100429	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing	{"Gammal Roseann S","Court Michael H","Haidar Cyrine E","Iwuchukwu Otito Frances","Gaur Aditya H","Alvarellos Maria","Guillemette Chantal","Lennox Jeffrey L","Whirl-Carrillo Michelle","Brummel Sean","Ratain Mark J","Klein Teri E","Schackman Bruce R","Caudle Kelly E","Haas David W"}	Clinical pharmacology and therapeutics	9			2015	26417955	PMC4785051	10.1002/cpt.269	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/atazanavir/2015/26417955.pdf
110016	100425	Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing	{"Johnson J A","Gong L","Whirl-Carrillo M","Gage B F","Scott S A","Stein C M","Anderson J L","Kimmel S E","Lee M T M","Pirmohamed M","Wadelius M","Klein T E","Altman R B"}	Clinical pharmacology and therapeutics	9			2011	21900891	PMC3187550	10.1038/clpt.2011.185	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/warfarin/2011/21900891.pdf
110034	100423	Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.	{"Phillips Elizabeth J","Sukasem Chonlaphat","Whirl-Carrillo Michelle","Müller Daniel J","Dunnenberger Henry M","Chantratita Wasun","Goldspiel Barry","Chen Yuan-Tsong","Carleton Bruce C","George Alfred L","Mushiroda Taisei","Klein Teri","Gammal Roseann S","Pirmohamed Munir"}	Clinical pharmacology and therapeutics	4	574-581	103	2018	29392710	PMC5847474	10.1002/cpt.1004	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/carbamazepine/2017/29392710.pdf
5407447	5290480	Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.	{"Duarte Julio D","Thomas Cameron D","Lee Craig R","Huddart Rachel","Agundez Jose A G","Baye Jordan F","Gaedigk Andrea","Klein Teri E","Lanfear David E","Monte Andrew A","Nagy Mohamed","Schwab Matthias","Stein C Michael","Uppugunduri Chakradhara Rao S","van Schaik Ron H N","Donnelly Roseann S","Caudle Kelly E","Luzum Jasmine A"}	Clinical pharmacology and therapeutics	7	\N	\N	2024	38951961	\N	10.1002/cpt.3351	\N	3	f	https://files.cpicpgx.org/data/guideline/publication/beta_blockers/2024/38951961.pdf
114759	\N	\N	{"Albuquerque et al"}	\N	\N	\N	\N	2013	\N	\N	10.2217/pme.13.56	\N	2	f	\N
110006	3070400	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors	{"Hicks J Kevin","Bishop Jeffrey R","Sangkuhl Katrin","Müller Daniel J","Ji Yuan","Leckband Susan G","Leeder J Steven","Graham Rebecca L","Chiulli Dana L","LLerena Adrián","Skaar Todd C","Scott Stuart A","Stingl Julia C","Klein Teri E","Caudle Kelly E","Gaedigk Andrea"}	Clinical pharmacology and therapeutics	5			2015	25974703	PMC4512908	10.1002/cpt.147	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/SSRI/2015/25974703.pdf
110011	100414	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants	{"Hicks J K","Swen J J","Thorn C F","Sangkuhl K","Kharasch E D","Ellingrod V L","Skaar T C","Müller D J","Gaedigk A","Stingl J C"}	Clinical pharmacology and therapeutics	1			2013	23486447	PMC3689226	10.1038/clpt.2013.2	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/TCA/2013/23486447.pdf
5407445	5290481	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy.	{"Robinson Katherine M","Eum Seenae","Desta Zeruesenay","Tyndale Rachel F","Gaedigk Andrea","Crist Richard C","Haidar Cyrine E","Myers Alan L","Samer Caroline F","Somogyi Andrew A","Zubiaur Pablo","Iwuchukwu Otito F","Whirl-Carrillo Michelle","Klein Teri E","Caudle Kelly E","Donnelly Roseann S","Kharasch Evan D"}	Clinical pharmacology and therapeutics	6	\N	\N	2024	38863207	\N	10.1002/cpt.3338	\N	3	f	https://files.cpicpgx.org/data/guideline/publication/methadone/2024/38863207.pdf
110003	100412	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing	{"Caudle Kelly E","Rettie Allan E","Whirl-Carrillo Michelle","Smith Lisa H","Mintzer Scott E","Lee Ming Ta Michael","Klein Teri E","Callaghan J Thomas"}	Clinical pharmacology and therapeutics	8			2014	25099164	PMC4206662	10.1038/clpt.2014.159	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/phenytoin/2014/25099164.pdf
110013	100417	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron	{"Bell Gillian C","Caudle Kelly E","Whirl-Carrillo Michelle","Gordon Ronald J","Hikino Keiko","Prows Cynthia A","Gaedigk Andrea","Agundez Jose A G","Sadhasivam Senthilkumar","Klein Teri E","Schwab Matthias"}	Clinical pharmacology and therapeutics	12			2016	28002639	PMC5479760	10.1002/cpt.598	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/ondansetron/2016/28002639.pdf
110022	100426	The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update	{"Ramsey Laura B","Johnson Samuel G","Caudle Kelly E","Haidar Cyrine E","Voora Deepak","Wilke Russell A","Maxwell Whitney D","McLeod Howard L","Krauss Ronald M","Roden Dan M","Feng Qiping","Cooper-DeHoff Rhonda M","Gong Li","Klein Teri E","Wadelius Mia","Niemi Mikko"}	Clinical pharmacology and therapeutics	6			2014	24918167	PMC4169720	10.1038/clpt.2014.125	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/simvastatin/2014/24918167.pdf
110077	100412	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.	{"Karnes Jason H","Rettie Allan E","Somogyi Andrew A","Huddart Rachel","Fohner Alison E","Formea Christine M","Lee Ming Ta Michael","Llerena Adrian","Whirl-Carrillo Michelle","Klein Teri E","Phillips Elizabeth J","Mintzer Scott","Gaedigk Andrea","Caudle Kelly E","Callaghan John T"}	Clinical pharmacology and therapeutics	8			2020	32779747	\N	\N	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/phenytoin/2020/32779747.pdf
110010	100415	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.	{"Goetz Matthew P","Sangkuhl Katrin","Guchelaar Henk-Jan","Schwab Matthias","Province Michael","Whirl-Carrillo Michelle","Symmans W Fraser","McLeod Howard L","Ratain Mark J","Zembutsu Hitoshi","Gaedigk Andrea","van Schaik Ron H","Ingle James N","Caudle Kelly E","Klein Teri E"}	Clinical pharmacology and therapeutics	5			2018	29385237	PMC5931215	10.1002/cpt.1007	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/tamoxifen/2017/29385237.pdf
110018	100422	Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update	{"Saito Y","Stamp L K","Caudle K E","Hershfield M S","McDonagh E M","Callaghan J T","Tassaneeyakul W","Mushiroda T","Kamatani N","Goldspiel B R","Phillips E J","Klein T E","Lee Mtm"}	Clinical pharmacology and therapeutics	6			2015	26094938	PMC4675696	10.1002/cpt.161	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/allopurinol/2015/26094938.pdf
1508721	100426	The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.	{"Cooper-DeHoff Rhonda M","Niemi Mikko","Ramsey Laura B","Luzum Jasmine A","Tarkiainen E Katriina","Straka Robert J","Gong Li","Tuteja Sony","Wilke Russell A","Wadelius Mia","Larson Eric A","Roden Dan M","Klein Teri E","Yee Sook Wah","Krauss Ronald M","Turner Richard M","Palaniappan Latha","Gaedigk Andrea","Giacomini Kathleen M","Caudle Kelly E","Voora Deepak"}	Clinical pharmacology and therapeutics	2	\N	\N	2022	35152405	\N	10.1002/cpt.2557	\N	59	f	https://files.cpicpgx.org/data/guideline/publication/statins/2022/publication.pdf
110017	100428	Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing	{"Relling M V","Gardner E E","Sandborn W J","Schmiegelow K","Pui C-H","Yee S W","Stein C M","Carrillo M","Evans W E","Klein T E"}	Clinical pharmacology and therapeutics	3	387-91	89	2011	21270794	PMC3098761	10.1038/clpt.2010.320	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/thiopurines/2011/21270794.pdf
110024	100428	Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update	{"Relling M V","Gardner E E","Sandborn W J","Schmiegelow K","Pui C-H","Yee S W","Stein C M","Carrillo M","Evans W E","Hicks J K","Schwab M","Klein T E"}	Clinical pharmacology and therapeutics	1			2013	23422873	PMC3604643	10.1038/clpt.2013.4	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/thiopurines/2013/23422873.pdf
417705	100416	Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy.	{"Crews Kristine R","Monte Andrew A","Huddart Rachel","Caudle Kelly E","Kharasch Evan D","Gaedigk Andrea","Dunnenberger Henry M","Leeder J Steven","Callaghan John T","Samer Caroline Flora","Klein Teri E","Haidar Cyrine E","Van Driest Sara L","Ruano Gualberto","Sangkuhl Katrin","Cavallari Larisa H","Müller Daniel J","Prows Cynthia A","Nagy Mohamed","Somogyi Andrew A","Skaar Todd C"}	Clinical pharmacology and therapeutics	1	\N	\N	2021	33387367	\N	10.1002/cpt.2149	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/opioids/2020/33387367.pdf
110002	100418	Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing	{"Birdwell Kelly A","Decker Brian","Barbarino Julia M","Peterson Josh F","Stein C Michael","Sadee Wolfgang","Wang Danxin","Vinks Alexander A","He Yijing","Swen Jesse J","Leeder J Steven","van Schaik R H N","Thummel Kenneth E","Klein Teri E","Caudle Kelly E","MacPhee Iain A M"}	Clinical pharmacology and therapeutics	3			2015	25801146	PMC4481158	10.1002/cpt.113	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/tacrolimus/2015/25801146.pdf
110019	100419	Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing	{"Caudle Kelly E","Thorn Caroline F","Klein Teri E","Swen Jesse J","McLeod Howard L","Diasio Robert B","Schwab Matthias"}	Clinical pharmacology and therapeutics	8			2013	23988873	PMC3831181	10.1038/clpt.2013.172	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/fluoropyrimidines/2013/23988873.pdf
110029	100419	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update	{"Amstutz Ursula","Henricks Linda M","Offer Steven M","Barbarino Julia","Schellens Jan H M","Swen Jesse J","Klein Teri E","McLeod Howard L","Caudle Kelly E","Diasio Robert B","Schwab Matthias"}	Clinical pharmacology and therapeutics	11			2017	29152729	PMC5760397	10.1002/cpt.911	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/fluoropyrimidines/2017/29152729.pdf
110009	100423	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Carbamazepine Dosing	{"Leckband Susan G","Kelsoe John R","Dunnenberger H Mark","George Alfred L","Tran Eric","Berger Reisel","Müller Daniel J","Whirl-Carrillo Michelle","Caudle Kelly E","Pirmohamed Munir"}	Clinical pharmacology and therapeutics	5			2013	23695185	PMC3748365	10.1038/clpt.2013.103	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/carbamazepine/2013/23695185.pdf
876861	826283	Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of aminoglycosides based on MT-RNR1 genotype.	{"McDermott John Henry","Wolf Joshua","Hoshitsuki Keito","Huddart Rachel","Caudle Kelly E","Whirl-Carrillo Michelle","Steyger Peter S","Smith Richard J H","Cody Neal","Rodriguez-Antona Cristina","Klein Teri E","Newman William G"}	Clinical pharmacology and therapeutics	5	\N	\N	2021	34032273	\N	10.1002/cpt.2309	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/aminoglycosides/2021/34032273.pdf
110032	100427	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes	{"Gonsalves Stephen G","Dirksen Robert T","Sangkuhl Katrin","Pulk Rebecca","Alvarellos Maria","Vo Teresa","Hikino Keiko","Roden Dan","Klein Teri","Mark Poler S","Patel Sephalie","Caudle Kelly E","Gordon Ronald","Brandom Barbara","Biesecker Leslie G"}	Clinical pharmacology and therapeutics	11			2018	30499100	\N	\N	\N	60	f	https://files.cpicpgx.org/data/guideline/publication/volatile_anesthetic_succinylcholine/2018/30499100.pdf
110021	100426	The Clinical Pharmacogenomics Implementation Consortium: Guideline for SLCO1B1 and Simvastatin-Induced Myopathy	{"Wilke R A","Ramsey L B","Johnson S G","Maxwell W D","McLeod H L","Voora D","Krauss R M","Roden D M","Feng Q","Cooper-Dehoff R M","Gong L","Klein T E","Wadelius M","Niemi M"}	Clinical pharmacology and therapeutics	5			2012	22617227	PMC3384438	10.1038/clpt.2012.57	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/simvastatin/2012/22617227.pdf
6605826	6478852	Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy.	{"Eadon Michael T","Hein David W","Andersen Michael A","Chapman Arlene B","Cooper-DeHoff Rhonda M","Desta Zeruesenay","Duarte Julio D","Elchynski Amanda L","Gaedigk Andrea","Karol Seth E","Limdi Nita A","Lteif Christelle","Sosinski Laura","Zubiaur Pablo","Whirl-Carrillo Michelle","Klein Teri E","Caudle Kelly E","Donnelly Roseann S","Agúndez José A G"}	Clinical pharmacology and therapeutics	9	\N	\N	2025	40974042	\N	10.1002/cpt.70071	\N	2	f	https://files.cpicpgx.org/data/guideline/publication/hydralazine/2025/40974042.pdf
110004	100414	Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update	{"Kevin Hicks J","Sangkuhl Katrin","Swen Jesse J","Ellingrod Vicki L","Müller Daniel J","Shimoda Kazutaka","Bishop Jeffrey R","Kharasch Evan D","Skaar Todd C","Gaedigk Andrea","Dunnenberger Henry M","Klein Teri E","Caudle Kelly E","Stingl Julia C"}	Clinical pharmacology and therapeutics	12			2016	27997040	PMC5478479	10.1002/cpt.597	\N	58	f	https://files.cpicpgx.org/data/guideline/publication/TCA/2016/27997040.pdf
\.


--
-- Data for Name: publication_supplement; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.publication_supplement (id, publicationid, description, url, version) FROM stdin;
726028	110016	\N	https://files.cpicpgx.org/data/guideline/publication/warfarin/2011/IWPC_dose_calculator.xls	1
725969	571448	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324-supplement.pdf	2
725970	571447	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/PPI/2020/32770672-supplement.pdf	2
725971	110006	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/SSRI/2015/25974703-supplement.pdf	2
725980	110011	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/TCA/2013/23486447-supplement.pdf	2
725981	110004	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/TCA/2016/27997040-supplement.pdf	2
725984	110014	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/abacavir/2012/22378157-supplement.pdf	2
725985	110015	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/abacavir/2014/24561393-supplement.pdf	2
725986	110027	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/allopurinol/2013/23232549-supplement.pdf	2
725987	110018	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/allopurinol/2015/26094938-supplement.pdf	2
725989	110008	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/atazanavir/2015/26417955-supplement.pdf	2
725990	110035	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/atomoxetine/2019/30801677-supplement.pdf	2
725991	110009	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/carbamazepine/2013/23695185-supplement.pdf	2
725992	110034	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/carbamazepine/2017/29392710-supplement.pdf	2
725993	110005	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2011/21716271-supplement.pdf	2
725994	110028	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2013/23698643-supplement.pdf	2
725997	110031	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/codeine/2012/22205192-supplement.pdf	2
726000	110033	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/codeine/2014/24458010-supplement.pdf	2
726001	110036	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/efavirenz/2019/31006110-supplement.pdf	2
726002	110019	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf	2
726003	110029	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/fluoropyrimidines/2017/29152729-supplement.pdf	2
726004	110023	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/ivacaftor/2014/24598717-supplement.pdf	2
726005	110013	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/ondansetron/2016/28002639-supplement.pdf	2
726007	417705	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/opioids/2020/33387367-supplement.pdf	2
726008	110007	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/pegintron/2013/24096968-supplement.pdf	2
726011	110003	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/phenytoin/2014/25099164-supplement.pdf	2
726012	110077	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/phenytoin/2020/32779747-supplement.pdf	2
726013	110000	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/rasburicase/2014/24787449-supplement.pdf	2
726014	110021	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/simvastatin/2012/22617227-supplement.pdf	2
726015	110022	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/simvastatin/2014/24918167-supplement.pdf	2
726019	110002	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/tacrolimus/2015/25801146-supplement.pdf	2
726020	110010	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/tamoxifen/2017/29385237-supplement.pdf	2
726021	110017	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/thiopurines/2011/21270794-supplement.pdf	2
726022	110024	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/thiopurines/2013/23422873-supplement.pdf	2
726023	110026	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/thiopurines/2018/30447069-supplement.pdf	2
726024	110032	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/volatile_anesthetic_succinylcholine/2018/30499100-supplement.pdf	2
726025	110001	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/voriconazole/2016/27981572-supplement.pdf	2
726027	110016	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/warfarin/2011/21900891-supplement.pdf	2
726029	110030	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/warfarin/2017/28198005-supplement.pdf	2
876862	876861	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/aminoglycosides/2021/34032273-supplement.pdf	1
1608552	1608551	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2022/35034351-supplement.pdf	1
1608553	1508721	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/statins/2022/supplement.pdf	1
2510457	2510456	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/G6PD/2022/36049896-supplement.pdf	1
3070388	3070387	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/serotonin_reuptake_inhibitor_antidepressants/2023/37032427-supplement.pdf	1
5407446	5407445	\N	https://files.cpicpgx.org/data/guideline/publication/methadone/2024/38863207-supplement.pdf	1
5407448	5407447	\N	https://files.cpicpgx.org/data/guideline/publication/beta_blockers/2024/38951961-supplement.pdf	1
6605827	6605826	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/hydralazine/2025/40974042-supplement.pdf	1
\.


--
-- Data for Name: recommendation; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.recommendation (id, guidelineid, drugid, implications, drugrecommendation, classification, phenotypes, activityscore, allelestatus, lookupkey, population, comments, version, dosinginformation, alternatedrugavailable, otherprescribingguidance) FROM stdin;
7211186	100421	RxNorm:190521	{"HLA-B": "Low or reduced risk of abacavir hypersensitivity"}	Use abacavir per standard dosing guidelines	Strong	{}	{}	{"HLA-B": "HLA-B*57:01 negative"}	{"HLA-B": "*57:01 negative"}	general	n/a	1	f	f	f
7211187	100421	RxNorm:190521	{"HLA-B": "Significantly increased risk of abacavir hypersensitivity"}	Abacavir is not recommended	Strong	{}	{}	{"HLA-B": "HLA-B*57:01 positive"}	{"HLA-B": "*57:01 positive"}	general	n/a	1	f	f	f
7211188	100422	RxNorm:519	{"HLA-B": "Low or reduced risk of allopurinol-induced SCAR"}	Use allopurinol per standard dosing guidelines	Strong	{}	{}	{"HLA-B": "HLA-B*58:01 negative"}	{"HLA-B": "*58:01 negative"}	general	n/a	1	f	f	f
7211189	100422	RxNorm:519	{"HLA-B": "Significantly increased risk of allopurinol-induced SCAR"}	Allopurinol is contraindicated	Strong	{}	{}	{"HLA-B": "HLA-B*58:01 positive"}	{"HLA-B": "*58:01 positive"}	general	n/a	1	f	f	f
7211190	826283	RxNorm:641	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
7211191	826283	RxNorm:641	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211192	826283	RxNorm:641	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211193	826283	ATC:D06AX07	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
7211194	826283	ATC:D06AX07	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211195	826283	ATC:D06AX07	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211196	826283	RxNorm:6099	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
7211197	826283	RxNorm:6099	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211198	826283	RxNorm:6099	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211199	826283	RxNorm:7934	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
7211200	826283	RxNorm:7934	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211201	826283	RxNorm:7934	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211202	826283	RxNorm:2049549	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
7211203	826283	RxNorm:2049549	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211204	826283	RxNorm:2049549	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211205	826283	RxNorm:10109	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
7211206	826283	RxNorm:10109	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211207	826283	RxNorm:10109	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211208	826283	RxNorm:10627	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
7211209	826283	RxNorm:10627	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211210	826283	RxNorm:10627	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211211	826283	RxNorm:3328	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
7211212	826283	RxNorm:3328	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211213	826283	RxNorm:3328	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211214	826283	RxNorm:7299	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
7211215	826283	RxNorm:7299	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211216	826283	RxNorm:7299	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211217	826283	RxNorm:7337	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
7211218	826283	RxNorm:7337	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211234	2405438	RxNorm:3445	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
7211219	826283	RxNorm:7337	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211220	826283	RxNorm:NA	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
7211221	826283	RxNorm:NA	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211222	826283	RxNorm:NA	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
7211223	2405438	RxNorm:7833	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
7211224	2405438	RxNorm:7833	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
7211225	2405438	RxNorm:7833	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
7211226	2405438	RxNorm:7833	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
7211227	2405438	RxNorm:7833	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
7211228	2405438	RxNorm:2551	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
7211229	2405438	RxNorm:2551	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
7211230	2405438	RxNorm:2551	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
7211231	2405438	RxNorm:2551	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
7211232	2405438	RxNorm:2551	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
7211233	2405438	RxNorm:3445	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
7211253	2405438	RxNorm:6572	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
7211235	2405438	RxNorm:3445	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
7211236	2405438	RxNorm:3445	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
7211237	2405438	RxNorm:3445	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
7211238	2405438	RxNorm:3639	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
7211239	2405438	RxNorm:3639	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
7211240	2405438	RxNorm:3639	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
7211241	2405438	RxNorm:3639	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
7211242	2405438	RxNorm:3639	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
7211243	2405438	RxNorm:4601	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
7211244	2405438	RxNorm:4601	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
7211245	2405438	RxNorm:4601	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
7211246	2405438	RxNorm:4601	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
7211247	2405438	RxNorm:4601	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
7211248	2405438	RxNorm:4815	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
7211249	2405438	RxNorm:4815	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
7211250	2405438	RxNorm:4815	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
7211251	2405438	RxNorm:4815	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
7211252	2405438	RxNorm:4815	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
7211254	2405438	RxNorm:6572	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
7211255	2405438	RxNorm:6572	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
7211256	2405438	RxNorm:6572	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
7211257	2405438	RxNorm:6572	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
7211258	2405438	RxNorm:7240	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
7211259	2405438	RxNorm:7240	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
7211260	2405438	RxNorm:7240	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
7211261	2405438	RxNorm:7240	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
7211262	2405438	RxNorm:7240	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
7211263	2405438	RxNorm:7517	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
7211264	2405438	RxNorm:7517	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
7211265	2405438	RxNorm:7517	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
7211266	2405438	RxNorm:7517	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
7211267	2405438	RxNorm:7517	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
7211268	2405438	RxNorm:7623	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
7211269	2405438	RxNorm:7623	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
7211270	2405438	RxNorm:7623	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
7212293	100413	RxNorm:42355	{"CYP2D6": "Reduced metabolism of fluvoxamine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}	Initiate therapy with recommended starting dose.	Moderate	{"CYP2D6": "Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5"}	general	n/a	1	f	f	f
7211271	2405438	RxNorm:7623	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
7211272	2405438	RxNorm:7623	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
7211273	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211274	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211275	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211276	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211277	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211278	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7212720	2405438	RxNorm:8120	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
7211279	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211280	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211281	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211282	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211283	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211284	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211285	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211286	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211315	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
7211287	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211288	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211289	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211290	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211291	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211292	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211293	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211294	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	No recommendation	No Recommendation	{"CYP2D6": "Indeterminate", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Intermediate Metabolizer"}	general	n/a	1	f	f	f
7211295	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211296	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211297	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211298	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211299	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211300	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211301	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211302	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211303	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211304	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211316	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
7211305	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Strong	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211306	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
7211307	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
7211308	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
7211309	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
7211310	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
7211311	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
7211312	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
7211313	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
7211314	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
7211317	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}	No recommendation	No Recommendation	{"CYP2D6": "Indeterminate", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
7212721	2405438	RxNorm:9071	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
7211318	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211319	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211320	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211321	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211322	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211398	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211323	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211324	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211325	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211326	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211327	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211328	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211623	2405438	RxNorm:5521	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute on chronic hemolysis	1	f	f	f
7211329	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211330	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211331	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211332	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211333	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211334	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211335	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211336	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211337	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211338	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211339	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211340	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Indeterminate", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211341	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211342	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211343	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211344	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211345	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211399	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211346	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211347	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211348	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211349	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211350	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211351	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211400	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211352	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211353	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211354	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211355	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211356	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211357	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211358	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211359	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211360	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211361	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211362	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211363	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Optional	{"CYP2D6": "Indeterminate", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	1	f	f	f
7213029	100416	RxNorm:10689	{"CYP2D6": "Reduced O-desmethyltramadol (active metabolite) formation"}	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.	Optional	{"CYP2D6": "Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5"}	general	n/a	1	f	f	f
7211364	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Optional	{"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	1	f	f	f
7211365	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211366	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211367	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211368	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211369	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211370	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211371	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211372	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211373	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211374	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211375	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211418	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211376	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211377	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211378	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211379	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211380	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211381	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211382	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211383	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211384	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211385	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
7211386	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Optional	{"CYP2D6": "Indeterminate", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	1	f	f	f
7211387	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Optional	{"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	1	f	f	f
7211624	2405438	RxNorm:5521	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
7211388	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Indeterminate"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211389	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Indeterminate"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211390	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Indeterminate"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211391	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Indeterminate"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211392	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211393	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211394	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211395	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211396	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211397	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Indeterminate"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211625	2405438	RxNorm:5521	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
7211401	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211402	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211403	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211404	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211405	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211406	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211407	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211408	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211409	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "Indeterminate", "CYP2C19": "Indeterminate"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211410	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
7211419	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211411	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211412	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211413	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211414	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211415	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211416	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211417	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211626	2405438	RxNorm:1151	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
7211420	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211421	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211422	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211423	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211424	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211425	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211426	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211487	100429	RxNorm:343047	{"UGT1A1": "n/a"}	No recommendation	No Recommendation	{"UGT1A1": "Indeterminate"}	{"UGT1A1": "n/a"}	{}	{"UGT1A1": "Indeterminate"}	general	UGT1A1*80 is in very high linkage disequilibrium with *28 and *37. In the rare event that *80 is detected but *28 and *37 are not, there are not enough clinical data to predict metabolizer status with certainty. However, if only *80 is interrogated and the patient is heterozygous or homozygous for *80, an intermediate or poor metabolizer phenotype may be inferred, respectively.	1	f	f	f
7211427	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211428	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211429	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211430	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211431	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211432	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	No recommendation	No Recommendation	{"CYP2D6": "Indeterminate", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Likely Intermediate Metabolizer"}	general	n/a	1	f	f	f
7211433	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211434	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211435	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211436	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211437	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211438	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211439	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211578	100423	RxNorm:2002	{"HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE", "HLA-B": "n/a"}	If patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.	Optional	{}	{}	{"HLA-A": "HLA-A*31:01 positive", "HLA-B": "No HLA-B Result"}	{"HLA-A": "*31:01 positive", "HLA-B": "No Result"}	CBZ-no alternatives	n/a	1	f	f	f
7211440	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211441	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211442	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211443	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211444	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211445	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7213030	100416	RxNorm:10689	{"CYP2D6": "Reduced O-desmethyltramadol (active metabolite) formation"}	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.	Optional	{"CYP2D6": "Intermediate Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75"}	general	n/a	1	f	f	f
7211446	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211447	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211448	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211449	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211450	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211451	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211452	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211453	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211454	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
7211455	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Indeterminate", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211456	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211457	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "No Result"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211458	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "No Result"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211459	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "No Result"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211460	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "No Result"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211461	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "No Result"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211462	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "No Result"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211463	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "No Result"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211464	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "No Result"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211465	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "No Result"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211466	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "No Result"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
7211627	2405438	RxNorm:1151	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs	1	f	f	f
7211467	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "No Result"}	general	n/a	1	f	f	f
7211468	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "No Result"}	general	n/a	1	f	f	f
7211469	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "No Result"}	general	n/a	1	f	f	f
7211470	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "No Result"}	general	n/a	1	f	f	f
7211471	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "No Result"}	general	n/a	1	f	f	f
7211472	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "No Result"}	general	n/a	1	f	f	f
7211473	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "No Result"}	general	n/a	1	f	f	f
7211474	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "No Result"}	general	n/a	1	f	f	f
7211475	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "No Result"}	general	n/a	1	f	f	f
7211732	100414	RxNorm:2597	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "No Result"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
7211476	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "No Result"}	general	n/a	1	f	f	f
7211477	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "No Result"}	general	n/a	1	f	f	f
7211478	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "Indeterminate", "CYP2C19": "No Result"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "No Result"}	general	n/a	1	f	f	f
7211479	2405438	RxNorm:1191	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	<= 1g per day	aspirin ≤ 1 g/day	1	f	f	f
7211480	2405438	RxNorm:1191	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	<= 1g per day	aspirin ≤ 1 g/day. Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs	1	f	f	f
7211481	2405438	RxNorm:1191	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	<= 1g per day	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for for acute exacerbation of chronic hemolysis.	1	f	f	f
7211482	2405438	RxNorm:1191	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	<= 1g per day	aspirin ≤ 1 g/day. Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
7211483	2405438	RxNorm:1191	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	<= 1g per day	aspirin ≤ 1 g/day	1	f	f	f
7211484	100429	RxNorm:343047	{"UGT1A1": "Reference UGT1A1 activity; very low likelihood of bilirubin-related discontinuation of atazanavir."}	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	Strong	{"UGT1A1": "Normal Metabolizer"}	{"UGT1A1": "n/a"}	{}	{"UGT1A1": "Normal Metabolizer"}	general	All studies correlating UGT1A1 genotypes with atazanavir adverse events have involved ritonavir boosting. However, concentration-time profiles are equivalent when boosted with either cobicistat or ritonavir (PMID 23532097), and bilirubin-related adverse events including discontinuation of atazanavir occur in a similar percentage of patients prescribed atazanavir with cobicistat or ritonavir (PMID 23532097). Associations between UGT1A1 genotype, bilirubin elevations, and atazanavir/r discontinuation therefore almost certainly translate to atazanavir/cobicistat. "reference" function refers to the UGT1A1 allele to which other alleles are compared.	1	f	f	f
7211485	100429	RxNorm:343047	{"UGT1A1": "Somewhat decreased UGT1A1 activity; low likelihood of bilirubin-related discontinuation of atazanavir."}	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	Strong	{"UGT1A1": "Intermediate Metabolizer"}	{"UGT1A1": "n/a"}	{}	{"UGT1A1": "Intermediate Metabolizer"}	general	All studies correlating UGT1A1 genotypes with atazanavir adverse events have involved ritonavir boosting. However, concentration-time profiles are equivalent when boosted with either cobicistat or ritonavir (PMID 23532097), and bilirubin-related adverse events including discontinuation of atazanavir occur in a similar percentage of patients prescribed atazanavir with cobicistat or ritonavir (PMID 23532097). Associations between UGT1A1 genotype, bilirubin elevations, and atazanavir/r discontinuation therefore almost certainly translate to atazanavir/cobicistat.	1	f	f	f
7211486	100429	RxNorm:343047	{"UGT1A1": "Markedly decreased UGT1A1 activity; high likelihood of bilirubin-related discontinuation of atazanavir."}	Consider an alternative agent particularly where jaundice would be of concern to the patient. If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%).	Strong	{"UGT1A1": "Poor Metabolizer"}	{"UGT1A1": "n/a"}	{}	{"UGT1A1": "Poor Metabolizer"}	general	All studies correlating UGT1A1 genotypes with atazanavir adverse events have involved ritonavir boosting. However, concentration-time profiles are equivalent when boosted with either cobicistat or ritonavir (PMID 23532097), and bilirubin-related adverse events including discontinuation of atazanavir occur in a similar percentage of patients prescribed atazanavir with cobicistat or ritonavir (PMID 23532097). Associations between UGT1A1 genotype, bilirubin elevations, and atazanavir/r discontinuation therefore almost certainly translate to atazanavir/cobicistat.	1	f	f	f
7211488	104243	RxNorm:38400	{"CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."}	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Moderate	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0"}	pediatrics	Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.	1	f	f	f
7211489	104243	RxNorm:38400	{"CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."}	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Moderate	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0"}	pediatrics	Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.	1	f	f	f
7211490	104243	RxNorm:38400	{"CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."}	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Moderate	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75"}	pediatrics	Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.	1	f	f	f
7211491	104243	RxNorm:38400	{"CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."}	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Moderate	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0"}	pediatrics	Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.	1	f	f	f
7211492	104243	RxNorm:38400	{"CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."}	Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Moderate	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5"}	pediatrics	Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.	1	f	f	f
7211493	104243	RxNorm:38400	{"CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."}	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Moderate	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25"}	pediatrics	Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.	1	f	f	f
7211494	104243	RxNorm:38400	{"CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."}	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Moderate	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0"}	pediatrics	Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.	1	f	f	f
7211495	104243	RxNorm:38400	{"CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."}	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Moderate	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0"}	pediatrics	Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.	1	f	f	f
7211496	104243	RxNorm:38400	{"CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."}	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Moderate	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75"}	pediatrics	Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.	1	f	f	f
7211497	104243	RxNorm:38400	{"CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."}	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Moderate	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0"}	pediatrics	Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.	1	f	f	f
7211498	104243	RxNorm:38400	{"CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."}	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Moderate	{"CYP2D6": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5"}	pediatrics	Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.	1	f	f	f
7211499	104243	RxNorm:38400	{"CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."}	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Moderate	{"CYP2D6": "Normal Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25"}	pediatrics	Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.	1	f	f	f
7211500	104243	RxNorm:38400	{"CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."}	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Moderate	{"CYP2D6": "Normal Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0"}	pediatrics	Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.	1	f	f	f
